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Nonfatal Scald-Related Burns Among Adults Aged ≥65 Years — 
United States, 2001–2006
Scalds, which are burns attributed to hot liquids or steam, 
account for 33%–58% of all patients hospitalized for burns in 
the United States (1–3). Adults aged ≥65 years have a worse 
prognosis than younger patients after scald burns because of 
age-related factors and comorbid medical conditions (4), and 
they are subject to more extensive medical treatment than 
younger adults. To estimate the number of emergency depart-
ment (ED) visits for nonfatal scald burns among U.S. adults 
aged ≥65 years and describe their characteristics, CDC analyzed 
ED visit data from the National Electronic Injury Surveillance 
System All Injury Program (NEISS-AIP) for 2001–2006. This 
report summarizes the results, which indicated that adults 
aged ≥65 years made an estimated 51,700 initial visits to EDs 
for nonfatal scald burns during 2001–2006, for an average of 
8,620 visits per year and an estimated average annual rate of 
23.8 visits per 100,000 population. Two thirds of visits were 
made by women. Most (76%) of the nonfatal scald injuries 
occurred at home; 42% were associated with hot food and 30% 
with hot water or steam. The findings in this report highlight 
the need for effective scald-prevention programs targeted to 
older persons.
NEISS–AIP, maintained by the Consumer Product Safety 
Commission (CPSC), collects data on initial ED visits for all 
types and causes of injuries. The system uses a nationally rep-
resentative sample of hospitals from 66 of the 100 NEISS–AIP 
hospitals that have 24-hour EDs in the United States (5). Data 
are collected from the medical records of new ED admissions, 
and only the most severe injury is recorded for each visit. Data 
include up to two product codes and a two-line narrative 
describing the circumstances of the injury (5).
For this analysis, a visit for nonfatal scald burn was defined 
as a visit by a patient aged ≥65 years to a hospital ED for scald 
burns at any time during the study period, 2001–2006. Visits 
were included if they met all three of the following condi-
tions: 1) the principal diagnosis was “scald,” “scald burn,” 
“scald related,” or “burn due to hot liquid or steam,” or the 
narrative describing burn circumstance contained a common 
product involving hot liquid or steam (e.g., pressure cooker, 
microwave, or bathtub), 2) the ED visit was the first visit for 
treatment of this scald burn, and 3) the scald-burn incident 
was not work related. Visits were excluded if the burn involved 
only smoke, fire, chemical, electrical, radiation, or flash burns. 
Patients who were dead on arrival or died shortly thereafter 
were excluded.
All ED narratives associated with nonfatal scald burns were 
reviewed. NEISS–AIP provides space for coding two products 
associated with the injury. For visits with two product codes, 
the code deemed to be more descriptive of the circumstances 
of the injury was retained in the analysis to create a mutually 
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exclusive set of product categories.* If multiple body parts were 
injured, only the most serious injury was used to create a set 
of mutually exclusive categories for analysis.
Visit estimates were based on weighted data from patients 
aged ≥65 years who were treated for nonfatal scald burns at 
EDs that reported data to NEISS-AIP. For each scald-related 
visit, NEISS–AIP assigns a sample weight based on its inverse 
probability of selection; these weights are summed to provide 
national estimates of nonfatal scald-related burns. Rates per 
100,000 persons were calculated using U.S. Census Bureau 
population estimates (6). Subgroup estimates with <20 visits or 
with a coefficient of variation >30% were considered unstable 
and were not reported. A direct variance estimation procedure 
that accounts for the sample weights and complex sample design 
was used to calculate 95% confidence intervals.
 A total of 705 ED visits for nonfatal scald burns were identi-
fied during the study period. No consistent temporal variation 
in the number of visits was observed across the 6 years,† or by 
hours of the day, days of the week, or seasons of the year. In 
536 (76%) of the 705 visits, the nonfatal scald burn occurred 
at home, most commonly in the kitchen (60%), dining area 
(20%), and bathroom (11%). Hot food was involved in 42% of 
burns (rate = 9.9 per 100,000), hot water or steam in 30% (rate 
= 7.2), and contact with cookware in 9% (rate = 2.2); 8% (rate 
= 1.9) of nonfatal scald burns were related to home or kitchen 
appliances, including 3% with microwave ovens. Among the 
705 visit narratives, 90% recorded the type of liquids associated 
with the burn, including hot (boiling) water (42%), hot oil 
(21%), coffee (15%), food (12%), steam (7%), and tea (3%).
Scald burn visits were more common among females (rate = 
27.2) than males (rate = 19.0). The most commonly affected 
body parts were upper extremities (arm/hand) (42%) and lower 
extremities (leg/foot) (38%), followed by head/neck (8%) and 
lower trunk (7%). Overall, 93% of ED visits resulted in dis-
charge after treatment; 4.2% of the patients were hospitalized, 
and 2% of the patients were transferred to other hospitals for 
more specialized care.
During 2001–2006, an estimated 139,770 initial ED 
visits by persons aged ≥65 years occurred for nonfatal fire or 
burn injuries, of which 53,600 (38%) were nonfatal scald 
burns. After excluding work-related scald burns, the remain-
ing 51,700 visits for nonfatal scald-related burns yielded a 
* If one of the two codes listed food, the other product code was recorded. For 
example, if the two codes referred to a microwave and food, microwave was 
recorded. If one of the two codes was water or steam, the other product code 
was recorded; water/steam was only assigned when no other information was 
available, because all scald burns involve a heated liquid or steam. For visits 
with two nonwater or nonfood product codes, the narratives were reviewed to 
choose which product was most descriptive of the injury circumstances.
† Number of visits by year: 2001 (110), 2002 (142), 2003 (92), 2004 (123), 
2005 (122), and 2006 (116).
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national estimated annual incidence of 23.8 per 100,000 
persons (Table 1). During the 6-year period, the estimated 
average annual number of initial ED visits for nonfatal scald-
related burns in persons aged ≥65 years was 8,620. The highest 
estimated annual numbers of ED visits were for scald burns 
to the arm/hand and leg/foot, and the highest number of 
ED visits were for scald burns caused by food or water/steam 
(Table 2).
Reported by: D Hungerford, DrPH, E Sullivent, MD, K Thomas, 
MPH, M Wald, MPH, Div of Injury Response, National Center for 
Injury Prevention and Control; M Galle, MD, EIS Officer, CDC.
Editorial Note: This report provides the first national estimate 
of ED visits for nonfatal scald burns in older adults. Compared 
with younger adults, older adults with scald-related burns 
are more frequently admitted to hospitals, experience longer 
intensive-care unit and hospital stays, have increased hospital 
mortality, and are transferred more frequently to rehabilita-
tion and long-term nursing facilities (3,4). The results of the 
analysis in this report indicate that, during 2001–2006, older 
adults made a substantial number of visits to U.S. EDs annu-
ally for scald burns. The burns resulted mainly in injuries to 
the arm/hand and leg/foot, were caused mostly by hot food 
and hot water or steam, and occurred predominantly in the 
kitchen, dining area, or bathroom. Greater awareness of the 
risk for these injuries and the use of simple precautions might 
help reduce these injuries (7,8) (Box).
The closest parallel analysis to the one reported here is the 
National Burn Registry (NBR) (2). However, NBR collects 
data on inpatients from burn centers rather than from ED 
visits to general hospitals, the source for NEISS–AIP data. The 
NBR results corroborate the findings of this report: the lead-
ing causes of nonfatal scald burns were contact with hot food, 
liquids, and steam. The NBR results also indicate that nonfatal 
scald burns occurred mainly in the kitchen, dining area, and 
bathroom. NBR data show that 14% of patients hospitalized 
with all types of burns were aged ≥60 years, and approximately 
35% of these patients sustained nonfatal scald burns from hot 
liquids, steam, or boiling tap water. Notably, the National Fire 
Protection Association determined that 41% of all scald burns 
from cooking equipment in 2006 were caused by microwave 
ovens (9).
The findings in this report are subject to at least four limita-
tions. First, the report underestimates the prevalence of non-
fatal scald burns because it does not include patients treated 
outside of hospital EDs (e.g., outpatient clinics, private doctor’s 
offices, and emergency walk-in clinics). Second, the report 
might underestimate the number of scald burns in patients 
with multiple injuries because the system records only one 
injury diagnosis. Third, narrative descriptions from medical 
TABLE 1. Average annual estimates and rates* of emergency 
department visits for nonfatal scald burns, adults aged ≥65 
years, by age group, sex, and disposition — National Electronic 
Injury Surveillance System (NEISS) All Injury Program, 
2001–2006
Characteristic No. (%) Rate (95% CI†)
Total 8,620 (100) 23.8 (20.0–27.6)
Age group (yrs)
65–79 6,460 (75) 24.9 (21.0–28.8)
≥80 2,160 (25) 21.0 (15.6–26.3)
Sex
Male 2,870 (33) 19.0 (14.8–23.3)
Female 5,740 (67) 27.2 (22.8–31.6)
Disposition
Treated, released 7,970 (93) 22.0 (18.6–25.4)
Hospitalized/transferred 510 (6) 1.4 (1.0–1.9)
Other§ 130 (2) 0.4 (0.0–0.7)
* Per 100,000 population, based on 2000 U.S. Census. Estimates might 
not sum to totals because of rounding.
† Confidence interval.
§ Patients left against medical advice or left without being seen by attend-
ing physician. Estimate are unstable because the coefficient of variation 
is >30%.
TABLE 2. Annual estimates and percentages* of emergency 
department visits for nonfatal scald burns, adults aged 
≥65 years, by affected body part and associated product — 
National Electronic Injury Surveillance System (NEISS) All 
Injury Program, 2001–2006
Burn site and source No. (%) (95% CI†)
Total 8,620 (100) (7,240–9,993)
Body part§
Head/neck 680 (8) (426–941)
Upper trunk 370 (4) (174–561)
Lower trunk 580 (7) (357–792)
Arm/hand 3,580 (42) (3,011–4,140)
Leg/foot 3,310 (38) (2,770–3,846)
Other¶ 90 (1) (6–153)
Unknown¶ 20 (0) (-22–67)
Associated product 
Food 3,580 (42) (2,867–4,298)
Water/steam 2,600 (30) (1,954–3,243)
Cookware** 780 (9) (518–1,043)
Home/kitchen appliances†† 690 (8) (481–901)
Bathroom products§§ 220 (3) (92–356)
Dining accessories¶¶ 220 (3) (92–345)
Other*** 480 (6) (275–675)
Unknown¶ 50 (1) (-9–102)
 * Estimates might not sum to totals because of rounding.
 † Confidence interval.
 § If multiple bodty parts were injured, only the most serious injury was 
recorded. Categories are mutually exclusive.
 ¶ Estimates are unstable because the coefficient of variation of the esti-
mate is >30%.
 ** Includes metal cookware and pressure cookers.
 †† Includes microwave, oven, range, and heaters.
 §§ Includes bathtub, shower, and whirlpool.
 ¶¶ Includes tableware and candles.
 *** Includes products and product categories (e.g., personal care items) 
for which estimates were unstable.
996 MMWR September 18, 2009
records did not always provide details or consistent informa-
tion on circumstances, products involved, injury severity, or 
mechanism of nonfatal scald burns. Finally, the number of 
ED visits in certain subgroups was small and did not support 
stable national estimates.
This report provides a baseline national estimate that can 
be used for comparison in future studies. The rapid growth in 
the U.S. population of older persons (10) makes monitoring 
of these injuries especially important. To reduce scald burns 
among older persons, further development of education and 
prevention strategies is needed, and these strategies should be 
evaluated for effectiveness.
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garments while cooking. Always ask for assistance if 
physically challenged.
•	 Plug	ovens	and	other	cooking	appliances	directly	into	
an outlet. Never use an extension cord for a cooking 
appliance; it can trip the user, which can cause hot food 
spills. Keep all appliance cords coiled and away from 
counter edges.
•	When	deep	frying,	prevent	contact	of	water	and	steam	
with hot oil; allow hot oil to cool before removal.
•	 To	prevent	spills,	turn	pot	handles	away	from	the	stove’s	
edge and use the back burner when possible.
•	 Only	use	dry	oven	mitts	or	potholders	when	moving	
hot food from ovens, microwave ovens, or stovetops.
•	 During	meals,	place	hot	items	in	the	center	of	the	table;	
use nonslip placemats instead of tablecloths.
•	 Treat	a	burn	right	away	by	putting	it	in	cool	water.	Cool	
the burn for 3–5 minutes and immediately seek medical 
attention.
Use Microwave Ovens Safely
•	 Place	the	microwave	oven	at	a	safe	height,	within	easy	
reach of all users, and lower than the face of the person 
using the microwave.
•	 Heat	foods	only	in	containers	or	dishes	that	are	safe	for	
microwave use. Never microwave uncracked eggs.
•	 To	prevent	steam	build-up,	remove	tight	lids	on	food	
containers, puncture plastic wraps, or use vented 
containers.
•	 Open	heated	food	containers	slowly,	away	from	face	or	
hands, to avoid steam scalds. Let cooked food stand for 




•	 Adjust	 thermostat	on	water	heater	 to	keep	hot	water	
<120°F. Install antiscald tempering valves or thermo-
static mixing valves.
•	 Before	using,	check	water	temperature	with	a	kitchen	
thermometer or test with your elbow, wrist, or hand 
with spread fingers.
•	 Start	to	fill	bathtub	with	cold	water	and	slowly	mix	with	
hot water. Avoid running water in other rooms during 
this time (it might increase the temperature of the water 
filling the bathtub) and turn off the hot water first.
* Adapted from recommendations of the American Burn Association and 
the National Fire Protection Association.
BOX. Suggested measures to reduce residential scald-related 
burns in older persons living independently at home*
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National, State, and Local Area 
Vaccination Coverage Among 
Adolescents Aged 13–17 Years — 
United States, 2008
In recent years, the Advisory Committee on Immunization 
Practices (ACIP) has recommended three newly licensed 
vaccines: meningococcal conjugate vaccine (MCV4; 1 dose); 
tetanus, diphtheria, acellular pertussis vaccine (Tdap; 1 dose); 
and (for girls) quadrivalent human papillomavirus vaccine 
(HPV4; 3 doses) (1). ACIP also recommends that adolescents 
receive recommended vaccinations that were missed during 
childhood: measles, mumps, rubella vaccine (MMR; 2 doses); 
hepatitis B vaccine (HepB; 3 doses); and varicella vaccine 
(VAR; 2 doses) (1). Since 2006, CDC has conducted the 
National Immunization Survey–Teen (NIS-Teen) to estimate 
vaccination coverage from a national sample of adolescents 
aged 13–17 years (2). This report summarizes results from 
the 2008 NIS-Teen and, for the first time, includes estimates 
for each of the 50 states and selected local areas. Nationally, 
vaccination coverage for the three most recently recom-
mended adolescent vaccinations and one childhood vaccina-
tion increased from 2007 to 2008: MCV4 (from 32.4% to 
41.8%), Tdap (from 30.4% to 40.8%), ≥1 dose of HPV4 
(from 25.1% to 37.2%), and ≥2 doses of VAR among those 
without disease history (from 18.8% to 34.1%). However, 
substantial variability in vaccination coverage was observed 
in 2008 among state and local areas and by race/ethnicity and 
poverty status. For the first time, the Healthy People 2010 target 
of 90% coverage among adolescents aged 13–15 years was met 
for MMR and HepB. Public health agencies should continue 
annual monitoring of adolescent vaccination coverage levels 
to identify trends and differences by geographic area, race/
ethnicity, and poverty status.
NIS-Teen collects vaccination information on adolescents 
aged 13–17 years* in the 50 states and selected local areas† 
using a random-digit–dialed sample of household telephone 
numbers. After parents/guardians grant permission, surveys 
are mailed to all of the adolescents’ vaccination providers 
identified by the parents/guardians to obtain vaccination his-
tories (2). During 2008, NIS-Teen was expanded; the survey 
was administered over four quarters compared with only the 
fourth quarter in 2006 and 2007 (2,3), and the analytic sample 
size increased nearly fivefold from 2006 and 2007 (2,3). For 
2008 NIS-Teen, the household response rate§ was 58.7%; a 
total of 17,835 adolescents with provider-verified vaccination 
records were included in this report. A description of NIS-
Teen methods and survey content has been published (2). 
Statistical differences in vaccination coverage were evaluated 
using chi square and t-tests and were considered statistically 
significant at p<0.05.
Among adolescents aged 13–17 years, vaccination coverage 
with ≥1 dose of tetanus, diphtheria toxoid vaccine (Td) or 
Tdap after age 10 years remained stable at 72.2%; however, 
coverage with ≥1 dose of Tdap increased from 30.4% in 2007 
to 40.8% in 2008 (Table 1). Vaccination coverage with ≥1 dose 
of MCV4 increased from 32.4% in 2007 to 41.8% in 2008. 
For HPV4, 37.2% of adolescent females had initiated the 
vaccination series (≥1 dose) in 2008, compared with 25.1% 
in 2007, and 17.9% of females had received ≥3 doses. Among 
adolescent females who initiated the HPV4 series, 79.4% had 
received their first dose at least 24 weeks before the interview 
date (the minimum period in which to complete the series) (4); 
of these, 59.6% (95% confidence interval [CI] = 55.5–63.5) 
had received ≥3 doses.
Vaccination coverage with ≥2 doses of MMR and ≥3 doses of 
HepB remained steady compared with 2007 (Table 1). Fewer 
adolescents had a reported history of varicella disease in 2008 
(59.8%) compared with 2007 (65.8%), and more adolescents 
had received ≥1 dose and ≥2 doses of VAR (Table 1).
Substantial differences were observed in vaccination cover-
age estimates among states and local areas (Table 2). Three 
states (Arizona, New Hampshire, and New York) had cover-
age of >50% for all three vaccines routinely recommended 
for adolescents (Tdap, MCV4, and HPV4). Other states with 
coverage >50% for at least one of the three vaccines, includ-
ing Colorado, New Mexico, Pennsylvania, and Wisconsin 
(≥1 dose of Tdap); Delaware, District of Columbia, Louisiana, 
Maryland, Massachusetts, New Jersey, Pennsylvania, Rhode 
Island, and Wisconsin (≥1 dose of MCV4); and Massachusetts, 
Rhode Island, and Vermont (≥1 dose of HPV4).
Variability in coverage was observed among racial/ethnic¶ 
groups and by poverty status** (Table 3). Blacks (87.9%) had 
lower vaccination coverage percentages than whites (93.7%) for 
* Eligible participants were born during January 1990–February 1996.
† Six local areas that received federal immunization grants were sampled separately: 
District of Columbia; Chicago, Illinois; New York, New York; Philadelphia 
County, Pennsylvania; Bexar County, Texas; and Houston, Texas.
 § The Council of American Survey Research Organizations (CASRO) household 
response rate is the product of the resolution rate (82.2%), screening 
completion rate (83.8%), and interview completion rate (85.2%).
 ¶ Respondents who self-identified as white, black, Asian, or American Indian/
Alaska Native were all considered non-Hispanic. Persons who self-identified 
as Hispanic might be of any race.
 ** Adolescents were classified as below poverty level if their total family income 
was less than the federal poverty level specified for the applicable family size 
and number of children aged <18 years. All others were classified as at or above 
the poverty level. Additional information is available at http://www.census.gov/
hhes/www/poverty.html. Poverty status was unknown for 744 adolescents.
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TABLE 1. Estimated vaccination coverage among adolescents aged 13–17 years,* by age at interview and selected vaccines and 
doses — National Immunization Survey–Teen, United States, 2008
Vaccines and doses
Age (yrs) Overall
13 14 15 16 17 2008 2007
(n = 3,455) (n = 3,641) (n = 3,666) (n = 3,731) (n = 3,342) (n = 17,835) (n = 2,947)
% (95% CI†) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
MMR§ ≥2 doses 90.3 (88.0–92.2) 91.8 (89.8–93.4) 90.1 (88.1–91.8) 86.2 (83.6–88.4) 88.1 (86.1–89.9) 89.3 (88.4–90.2) 88.9 (87.3–90.4)
Hepatitis B ≥3 doses 92.8 (91.2–94.1) 93.1 (91.5–94.3) 89.6 (87.0–91.7) 81.5 (78.6–84.1) 82.9 (80.7–84.8) 87.9 (86.9–88.8) 87.6 (86.0–89.0)
Varicella
History of varicella disease¶ 42.3 (39.2–45.5) 50.1 (47.1–53.1) 62.8 (59.5–66.0) 68.2 (65.1–71.2) 74.8 (71.3–78.1) 59.8 (58.4–61.3)** 65.8 (63.5–68.0)
Among adolescents without 
history of disease:
≥1 dose 89.6 (87.1–91.6) 85.2 (81.6–88.2) 80.2 (75.2–84.4) 76.5 (71.8–80.6) 68.2 (61.7–74.1) 81.9 (80.2–83.5)** 75.7 (72.2-79.0)
≥2 doses 40.5 (36.4–44.9) 34.5 (29.9–39.3) 34.2 (29.1–39.7) 28.1 (22.9–34.0) 26.9 (18.9–36.8) 34.1 (31.8–36.6)** 18.8 (15.9-22.0) 
History of disease or received 
≥1 dose varicella vaccine
94.0 (92.5–95.2) 92.6 (90.7–94.2) 92.6 (90.5–94.3) 92.5 (91.0–93.8) 92.0 (90.5–93.3) 92.7 (92.0–93.4) 91.7 (90.3–92.9)
Td or Tdap since age 10 years††
≥1 dose Td or Tdap 64.1 (61.0–67.2) 69.7 (66.5–72.7) 77.7 (75.2–80.0) 74.8 (71.9–77.5) 73.7 (70.7–76.6) 72.2 (70.8–73.4) 72.3 (70.3-74.3)
≥1 dose Tdap 51.9 (48.7–55.1) 47.3 (44.0–50.6) 41.5 (38.2–44.9) 35.1 (32.1–38.1) 28.7 (25.5–32.1) 40.8 (39.3–42.3)** 30.4 (28.2-32.7)
MCV4 ≤1 dose§§ 42.0 (38.8–45.1) 43.0 (39.8–46.4) 46.4 (43.0–49.7) 40.5 (37.4–43.6) 36.7 (33.5–40.0) 41.8 (40.3–43.2)** 32.4 (30.2–34.7)
HPV4¶¶
≥1 dose 35.2 (31.1–39.6) 33.8 (29.6–38.2) 42.2 (37.5–47.2) 35.7 (31.7–39.9) 38.5 (33.3–43.9) 37.2 (35.2–39.3)** 25.1 (22.3-28.1)
≥3 doses 14.5 (11.9–17.5) 16.6 (13.6–20.2) 18.5 (15.5–21.8) 18.8 (15.6–22.4) 20.9 (16.3–26.3) 17.9 (16.3–19.6) —***
 * Adolescents (N = 17,835) in 2008 NIS-Teen were born during January 1990–February 1996. 
 † Confidence interval.
 § Measles, mumps, and rubella vaccine.
 ¶ By parent/guardian report or provider records.
 ** Significant difference compared with NIS-Teen 2007 overall estimates (p<0.05).
 †† Includes percentages receiving tetanus and diphtheria toxoids vaccine (Td), tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), or tetanus-unknown 
type vaccine.
 §§ Includes percentages receiving meningococcal conjugate vaccine (MCV4) or meningococcal-unknown type vaccine.
 ¶¶ Quadrivalent human papillomavirus vaccine. Percentages reported among females only (n = 8,607); HPV4 vaccine is not recommended for males.
 *** Estimate not reported because unweighted sample size for the denominator was <30.
TABLE 2. Estimated vaccination coverage among adolescents aged 13–17 years,* by state and selected areas and selected 
vaccines and doses — National Immunization Survey–Teen, United States, 2008
Vaccine doses routinely recommended during childhood 
(adolescent catch-up vaccines) Vaccine doses routinely recommended for adolescents
≥2 MMR† ≥3 HepB§ ≥1 VAR¶ ≥1 Td or Tdap** ≥1 Tdap ≥1 MCV4†† ≥1 HPV4§§
State/Area % (95% CI¶¶) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
United States 89.3 (88.4–90.2) 87.9 (86.9–88.8) 81.9 (80.2–83.5) 72.2 (70.8–73.4) 40.8 (39.3–42.3) 41.8 (40.3–43.2) 37.2 (35.2–39.3)
Alabama 89.8 (85.7–92.8) 68.2 (62.3–73.5) 71.2 (61.6–79.2) 70.1 (64.6–75.1) 44.0 (38.3–49.8) 29.9 (24.8–35.5) 32.8 (25.5–41.1)
Alaska 84.4 (79.3–88.5) 86.9 (82.3–90.5) 66.7 (55.4–76.4)*** 68.3 (62.2–73.7) 42.1 (36.2–48.3) 30.5 (25.1–36.5) 38.8 (30.6–47.8)
Arizona 82.4 (75.7–87.6) 83.9 (77.9–88.5) 85.4 (74.1–92.3) 74.0 (66.5–80.3) 53.8 (46.4–61.0) 51.5 (44.2–58.7) 50.5 (40.3–60.7)***
Arkansas 90.2 (86.3–93.1) 90.9 (87.1–93.7) 84.9 (77.5–90.1) 46.1 (40.4–52.0) 23.8 (19.2–29.1) 14.5 (10.8–19.1) 22.4 (16.2–30.2)
California 91.9 (86.9–95.1) 89.9 (83.8–93.8) 92.9 (87.4–96.1) 71.3 (64.1–77.5) 43.7 (36.3–51.4) 48.0 (40.5–55.6) 46.6 (36.3–57.3)***
Colorado 91.0 (86.8–94.0) 94.6 (91.0–96.8) 85.3 (77.3–90.8) 77.4 (70.8–82.9) 63.0 (55.9–69.5) 32.4 (26.3–39.2) 33.5 (25.5–42.6)
Connecticut 95.7 (91.5–97.9) 98.4 (94.8–99.5) 97.6 (91.6–99.4) 79.8 (73.2–85.0) 45.4 (38.5–52.5) 45.2 (38.2–52.4) 45.0 (35.6–54.8)
Delaware 94.8 (90.4–97.3) 95.2 (91.9–97.2) 86.1 (78.7–91.2) 78.6 (72.9–83.3) 43.1 (36.9–49.6) 58.6 (52.1–64.7) 46.8 (37.9–56.0)
District of Columbia 94.6 (89.9–97.2) 94.8 (90.7–97.2) 96.4 (92.1–98.4) 84.7 (79.9–88.6) 32.7 (27.1–38.9) 58.1 (51.7–64.2) 38.7 (30.0–48.3)
Florida 92.3 (85.8–96.0) 92.8 (87.6–96.0) 80.0 (66.1–89.1)*** 79.4 (70.3–86.2) 29.0 (22.6–36.2) 33.6 (26.7–41.2) 36.7 (26.7–48.0)***
Georgia 92.8 (87.4–96.0) 91.6 (87.4–94.5) 91.4 (83.2–95.8) 70.9 (64.6–76.4) 37.8 (31.6–44.4) 41.6 (35.2–48.3) 18.5 (13.0–25.5)
Hawaii 91.4 (86.9–94.4) 93.1 (88.9–95.8) 89.7 (82.4–94.3) 71.6 (65.7–76.9) 32.0 (26.5–38.0) 44.1 (38.1–50.3) 40.2 (32.3–48.6)
Idaho 73.2 (66.4–79.0) 73.1 (66.4–78.8) 61.1 (47.3–73.3)*** 51.3 (44.5–58.0) 31.7 (25.7–38.3) 29.9 (24.1–36.5) 28.4 (20.5–38.0)
Illinois 89.5 (85.1–92.7) 93.2 (89.5–95.7) 74.2 (65.0–81.6) 72.9 (67.7–77.6) 45.4 (39.9–51.0) 41.9 (36.5–47.6) 27.0 (20.8–34.3)
  Chicago 83.4 (78.3–87.5) 90.2 (85.5–93.5) 79.3 (70.8–85.8) 71.8 (65.6–77.3) 44.2 (38.0–50.5) 41.1 (35.1–47.5) 28.6 (20.8–37.9)
  Rest of state 91.1 (84.8–95.0) 94.0 (88.6–96.9) 73.0 (60.2–82.8)*** 73.5 (66.4–79.5) 45.5 (38.4–52.9) 42.8 (35.7–50.2) 25.7 (18.0–35.3)
Indiana 91.7 (88.2–94.1) 86.2 (81.4–90.0) 70.4 (59.9–79.1) 53.6 (47.4–59.7) 31.2 (26.1–36.7) 31.8 (26.5–37.8) 26.1 (19.8–33.6)
Iowa 86.4 (81.7–90.1) 79.2 (73.9–83.6) 68.4 (56.4–78.4)*** 65.9 (59.4–71.8) 43.5 (37.4–49.9) 31.9 (26.4–38.0) 41.9 (32.6–51.9)
Kansas 84.1 (78.3–88.6) 71.4 (64.6–77.4) 62.5 (49.5–73.9)*** 69.9 (63.4–75.6) 46.8 (40.1–53.7) 25.6 (20.0–32.3) 30.1 (21.7–40.0)
Kentucky 96.2 (93.2–97.9) 93.3 (89.3–95.9) 74.7 (63.9–83.1) 82.0 (76.2–86.6) 28.1 (22.6–34.3) 30.9 (25.3–37.0) 26.3 (18.8–35.4)
Louisiana 89.0 (84.8–92.2) 85.1 (80.3–88.9) 68.9 (57.3–78.6)*** 74.9 (69.3–79.8) 35.3 (29.8–41.3) 53.6 (47.5–59.6) 36.6 28.3–45.6
Maine 92.6 (88.9–95.2) 81.4 (76.0–85.7) 89.7 (81.5–94.5) 75.0 (69.1–80.1) 43.0 (36.9–49.3) 35.6 (29.9–41.7) 40.3 (32.2–49.0)
Maryland 92.3 (88.1–95.1) 91.2 (87.1–94.1) 86.7 (78.4–92.1) 79.0 (73.0–83.9) 37.9 (32.2–44.0) 54.6 (48.2–60.7) 41.1 (32.4–50.5)
Massachusetts 99.5 (98.2–99.8) 97.4 (95.0–98.6) 95.0 (85.1–98.4) 94.4 (90.5–96.8) 43.3 (37.2–49.7) 55.9 (49.4–62.2) 53.3 (43.8–62.6)
Michigan 94.6 (91.4–96.7) 92.8 (89.3–95.2) 86.8 (77.5–92.6) 69.9 (63.9–75.3) 33.6 (27.9–39.8) 39.9 (33.8–46.2) 32.3 (23.8–42.1)
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protection against varicella (i.e., history of varicella disease or 
≥1 dose of VAR) and Tdap (36.0% versus 41.7%). Overall, the 
percentage of adolescents with history of varicella or ≥1 dose of 
VAR was lower for those living below the poverty level (88.9%) 
compared with children at or above poverty (93.5%). Compared 
with whites, coverage was higher among American Indian/Alaska 
Natives for MMR (93.9% versus 89.9%) and Td/Tdap (81.4% 
versus 71.6%). Coverage also was higher among Hispanics than 
whites for ≥1 dose of MCV4 (46.8% versus 39.7%) and ≥1 dose 
of HPV4 (44.4% versus 35.0%). Adolescent females living below 
the poverty level had a higher vaccination coverage percentage 
for ≥1 dose of HPV4 (46.4%) than adolescent females living at 
or above the poverty level (35.8%).
Healthy People 2010 established vaccination coverage targets 
of 90% for adolescents aged 13–15 years for ≥3 doses of HepB, 
≥2 doses of MMR, ≥1 dose of Td or Tdap, and ≥1 dose of 
VAR, among those without history of disease (5). For the first 
time, Healthy People 2010 targets were achieved for ≥3 doses 
of HepB (91.8%, CI = 90.7–92.8) and ≥2 doses of MMR 
(90.7%, CI = 89.6–91.8). Vaccination coverage remained 
stable at 70.7% (CI = 69.0–72.4) for ≥1 dose of Td or Tdap, 
and increased from 80.2% in 2007 to 85.5% (CI = 83.5–87.3) 
in 2008 for ≥1 dose of VAR.
Reported by: S Stokley, MPH, C Dorell, MD, D Yankey, MS, 
Immunization Svc Div, National Center for Immunization and 
Respiratory Diseases, CDC.
TABLE 2. (Continued) Estimated vaccination coverage among adolescents aged 13–17 years,* by state and selected areas and 
selected vaccines and doses — National Immunization Survey–Teen, United States, 2008
Vaccine doses routinely recommended during childhood 
(adolescent catch-up vaccines) Vaccine doses routinely recommended for adolescents
≥2 MMR† ≥3 HepB§ ≥1 VAR¶ ≥1 Td or Tdap** ≥1 Tdap ≥1 MCV4†† ≥1 HPV4§§
State/Area % (95% CI¶¶) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Minnesota 90.1 (85.5–93.4) 89.7 (85.4–92.9) 84.8 (76.2–90.6) 88.7 (84.2–92.0) 40.7 (34.8–46.8) 38.9 (33.1–45.1) 33.6 (26.4–41.7)
Mississippi 94.5 (91.6–96.5) 60.8 (55.0–66.2) 40.0 (31.0–49.8) 28.7 (23.7–34.3) 19.6 (15.3–24.7) 14.8 (10.9–19.8) 15.8 (10.6–23.0)
Missouri 84.2 (79.0–88.4) 87.0 (82.4–90.5) 62.7 (51.6–72.6)*** 67.9 (62.0–73.3) 44.1 (38.1–50.2) 35.3 (29.9–41.2) 31.6 (23.9–40.6)
Montana 84.1 (78.6–88.3) 75.2 (69.4–80.1) 70.1 (58.4–79.7)*** 69.1 (62.6–74.8) 44.2 (37.8–50.7) 17.8 (13.1–23.6) —†††
Nebraska 88.5 (83.7–92.0) 90.6 (86.1–93.8) 86.1 (78.3–91.4) 71.5 (65.6–76.7) 42.2 (36.5–48.0) 37.2 (31.8–42.9) 29.5 (23.0–37.0)
Nevada 88.8 (83.5–92.6) 82.7 (76.6–87.4) 64.8 (53.0–75.0)*** 69.0 (61.6–75.5) 45.9 (38.6–53.2) 29.6 (23.3–36.9) 30.0 (21.2–40.4)
New Hampshire 94.9 (90.0–97.5) 92.7 (88.2–95.5) 93.2 (85.7–96.9) 84.2 (77.1–89.4) 53.1 (45.8–60.2) 54.6 (47.3–61.7) 54.4 (44.3–64.1)
New Jersey 91.8 (87.6–94.6) 94.5 (91.0–96.7) 86.2 (78.9–91.2) 78.1 (72.4–83.0) 43.0 (36.9–49.3) 60.6 (54.3–66.6) 43.0 (34.3–52.1)
New Mexico 84.2 (78.2–88.7) 83.1 (76.5–88.1) 69.0 (58.7–77.8) 75.1 (68.8–80.6) 50.4 (43.7–57.0) 39.6 (33.3–46.3) 48.3 (38.4–58.4)***
New York 92.6 (89.7–94.8) 93.0 (89.7–95.3) 88.7 (83.0–92.6) 85.5 (81.9–88.5) 53.8 (48.9–58.6) 56.0 (51.1–60.8) 50.2 (43.1–57.3)
  New York City 89.7 (84.0–93.5) 90.9 (86.0–94.1) 85.7 (75.1–92.3) 85.4 (80.0–89.5) 49.4 (42.3–56.5) 53.5 (46.4–60.5) 48.3 (38.0–58.7)***
  Rest of state 94.6 (91.2–96.8) 94.5 (89.3–97.3) 90.9 (84.1–95.0) 85.6 (80.6–89.5) 56.8 (50.1–63.2) 57.7 (51.1–64.0) 51.5 (41.9–61.0)
North Carolina 82.2 (76.4–86.8) 81.4 (75.2–86.4) 57.7 (47.1–67.7)*** 63.6 (56.9–69.8) 28.0 (22.8–33.8) 30.7 (25.2–36.9) 34.4 (26.3–43.6)
North Dakota 93.7 (90.4–96.0) 87.9 (83.4–91.3) 76.1 (66.1–83.8) 75.0 (69.4–79.9) 47.8 (42.2–53.5) 47.4 (41.7–53.1) 28.7 (21.9–36.7)
Ohio 84.8 (79.7–88.8) 76.9 (71.0–81.9) 77.4 (65.9–85.9)*** 57.8 (51.3–64.1) 30.6 (25.2–36.7) 37.7 (31.7–44.0) 29.1 (21.6–37.9)
Oklahoma 90.2 (85.9–93.3) 88.9 (84.0–92.4) 83.1 (73.6–89.6) 59.5 (53.1–65.5) 28.6 (23.3–34.5) 25.1 (20.0–30.9) 35.5 (27.3–44.7)
Oregon 87.7 (82.3–91.6) 88.0 (81.5–92.4) 89.0 (79.6–94.3) 64.1 (56.6–71.0) 38.9 (32.2–45.9) 29.6 (23.7–36.3) 34.8 (25.6–45.3)
Pennsylvania 94.6 (91.5–96.6) 95.3 (91.8–97.3) 94.2 (89.7–96.8) 82.0 (77.1–86.0) 51.2 (45.8–56.6) 59.7 (54.2–65.1) 46.1 (38.7–53.7)
Philadelphia County 89.3 (84.7–92.6) 93.3 (89.4–95.8) 91.8 (85.8–95.4) 79.7 (73.9–84.5) 48.6 (42.4–54.8) 66.3 (60.1–72.1) 51.8 (43.3–60.3)
  Rest of state 95.5 (91.4–97.7) 95.2 (90.4–97.6) 94.9 (89.5–97.6) 81.9 (76.0–86.7) 48.6 (42.1–55.2) 56.2 (49.5–62.6) 46.5 (37.5–55.7)
Rhode Island 96.3 (92.9–98.1) 98.4 (96.7–99.3) 97.8 (89.1–99.6) 91.5 (86.5–94.8) 41.6 (34.7–48.9) 62.6 (55.3–69.5) 54.7 (44.2–64.8)***
South Carolina 90.9 (87.0–93.7) 92.0 (88.4–94.5) 61.0 (51.3–69.9) 53.7 (47.8–59.5) 27.3 (22.4–32.9) 25.1 (20.1–30.8) 18.7 (13.2–25.9)
South Dakota 86.7 (82.1–90.2) 65.2 (59.2–70.7) 52.7 (41.0–64.1)*** 45.3 (39.3–51.4) 19.3 (15.1–24.4) 14.0 (10.3–18.9) 45.9 (37.9–54.1)
Tennessee 85.9 (80.5–90.0) 82.4 (76.1–87.3) 72.0 (62.4–79.9) 50.3 (44.1–56.4) 34.3 (28.7–40.3) 36.5 (30.9–42.6) 29.6 (21.6–39.2)
Texas 81.6 (75.6–86.5) 86.5 (81.2–90.5) 79.4 (66.5–88.2)*** 79.3 (73.4–84.3) 40.8 (34.0–48.1) 37.4 (30.9–44.3) 31.6 (23.2–41.5)
  Bexar County 82.2 (75.6–87.2) 83.9 (76.7–89.3) 83.6 (71.0–91.4)*** 77.7 (71.0–83.2) 42.0 (35.0–49.3) 43.2 (36.2–50.5) 40.7 (30.6–51.7)***
  Houston 87.0 (80.2–91.7) 86.4 (79.3–91.3) 86.0 (75.6–92.5) 73.0 (63.8–80.6) 42.6 (34.0–51.8) 51.9 (42.9–60.7) 30.2 (20.3–42.4)***
  Rest of state 80.1 (71.3–86.7) 86.8 (79.0–92.0) 78.2 (57.4–90.5)*** 80.2 (71.5–86.8) 41.5 (32.0–51.8) 34.6 (25.9–44.5) —
Utah 82.6 (76.5–87.4) 70.2 (63.1–76.5) 67.5 (53.7–78.7)*** 62.7 (54.9–69.9) 46.8 (39.4–54.3) 31.3 (24.9–38.6) —
Vermont 95.2 (91.5–97.4) 94.8 (91.4–96.9) 93.0 (83.8–97.2) 79.8 (73.7–84.8) 49.2 (42.5–55.9) 20.0 (15.2–25.8) 50.4 (40.9–59.8)
Virginia 83.0 (76.7–87.9) 83.7 (76.8–88.8) 69.4 (57.6–79.1)*** 70.3 (63.6–76.3) 49.1 (42.1–56.1) 43.8 (37.1–50.8) 40.6 (31.9–50.0)
Washington 78.0 (71.7–83.3) 81.3 (75.6–85.9) 78.9 (67.8–87.0) 64.2 (57.4–70.5) 34.7 (28.7–41.2) 40.0 (33.5–46.8) 46.5 (37.1–56.1)
West Virginia 80.8 (75.1–85.5) 72.4 (66.2–77.8) 66.5 (55.0–76.3)*** 44.7 (38.3–51.2) 24.1 (19.1–29.9) 30.2 (24.6–36.4) 33.6 (25.7–42.6)
Wisconsin 93.0 (89.0–95.7) 87.8 (82.4–91.6) 84.4 (73.4–91.4) 75.4 (69.1–80.8) 53.8 (47.1–60.4) 52.2 (45.5–58.9) 47.0 (37.0–57.2)***
Wyoming 87.3 (82.2–91.1) 80.9 (75.1–85.7) 69.5 (58.8–78.5) 79.1 (73.1–84.1) 28.3 (23.0–34.3) 32.8 (27.2–39.0) 36.2 (27.7–45.7)
 * Adolescents (N = 17,835) in the 2008 NIS-Teen were born during January 1990–February 1996.
 † ≥2 doses of measles, mumps, and rubella vaccine.
 § ≥3 doses of hepatitis B vaccine.
 ¶ ≥1 dose of varicella vaccine among adolescents without a reported history of varicella disease.
 ** Tetanus and diphtheria toxoids vaccine (Td), or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), or tetanus-unknown vaccine on or after age 10 years.
 †† ≥1 dose of meningococcal conjugate vaccine or meningococcal-unknown type vaccine.
 §§ ≥1 dose of quadrivalent human papillomavirus vaccine.  Percentage reported among females only (n = 8,607); HPV4 vaccine is not recommended for males.
 ¶¶ Confidence interval.
 *** Estimate might not be reliable; CI width >20.
 ††† Estimate not reported because unweighted sample size for the denominator was <30.
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Editorial Note: This is the third annual report of national 
adolescent vaccination coverage based on provider-reported 
vaccination histories from NIS-Teen and the first report of 
state and local area estimates. Coverage levels for vaccines 
routinely recommended for adolescents continued to increase 
nationally; however, coverage varied substantially among state 
and local areas. Differences also were observed by race/ethnicity 
and poverty status including higher HPV4 (≥1 dose) coverage 
among Hispanic females compared with whites and among 
adolescents living below compared with those living at or 
above the poverty level.
The wide variation in adolescent coverage levels among states 
might be the result of changes in immunization policies, recent 
experiences with outbreaks of vaccine preventable diseases, or 
efforts to remove cost as a barrier to vaccination. For example, 
Colorado, a state with high Tdap coverage, implemented a 
Tdap requirement for 6th and 10th grade students during the 
2007–08 school year, incrementally increasing the grades cov-
ered until 2011, when the requirement will apply to all students 
in grades 6–12 (J. Reynolds, Colorado Immunization Program, 
personal communication, 2009). During the 2007–08 school 
year, 22 states reported having a requirement for a tetanus-
containing vaccine for entry into middle school (only seven 
specified Tdap formulation); no states reported requirements 
for MCV4 or HPV4 vaccines.†† In New Hampshire, an 
increase in funds contributed by insurance companies for 
state purchase of vaccine soon after HPV4 was recommended 
allowed the state to provide universal coverage to females aged 
11–18 years (M. Bobinsky, New Hampshire Immunization 
Program, personal communication, 2009). However, in 2008, 
only seven states provided universal coverage of all routinely 
TABLE 3. Estimated vaccination coverage among adolescents aged 13–17 years,* by race/ethnicity,† poverty level,§ and selected 






Below poverty  
level
At or above 
poverty level
(n = 12,628) (n = 1,934) (n = 2,017) (n = 234) (n = 334) (n = 2,140) (n = 14,951)
% (95% CI¶) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
MMR** ≥2 doses 89.9 (88.8–90.8) 89.1 (86.5–91.2) 87.5 (84.4–90.0) 93.9 (88.3–96.9)†† 87.2 (77.4–93.1) 87.1 (84.1–89.6) 89.6 (88.6–90.6)
Hepatitis B ≥3 doses 88.1 (87.0–89.1) 86.0 (83.3–88.3) 89.8 (87.0–92.0) 86.6 (77.6–92.4) 89.9 (80.0–95.2) 86.7 (83.9–89.1) 88.0 (87.0–89.1)
Varicella
History of varicella 
disease§§




≥1 dose 82.8 (81.0–84.5) 74.0 (68.4–78.9)†† 84.5 (79.0–88.8) 83.5 (68.4–92.2)¶¶ 89.1 (82.0–93.6) 77.0 (71.1–82.1)†† 82.9 (81.2–84.4)
≥2 doses 31.6 (29.5–33.9) 35.0 (28.1–42.6) 38.5 (31.8–45.7) —*** 36.1 (24.0–50.3)¶¶ 35.8 (28.9–43.4) 33.9 (31.5–36.3)
History of disease 
or received ≥1 dose 
varicella vaccine
93.7 (93.0–94.3) 87.9 (85.1–90.2)†† 93.0 (90.4–95.0) 94.4 (88.9–97.3) 95.4 (92.4–97.3) 88.9 (85.8–91.3)†† 93.5 (92.8–94.1)
Td or Tdap since age 
10 years†††
≥1dose Td or Tdap 71.6 (70.1–73.0) 71.4 (67.6–74.9) 74.1 (70.0–77.8) 81.4 (72.6–87.8)†† 76.9 (67.2–84.4) 70.9 (67.0–74.4) 72.7 (71.3–74.1)
≥1dose Tdap 41.7 (40.2–43.3) 36.0 (31.9–40.2)†† 41.9 (37.5–46.5) 43.5 (31.7–56.1)¶¶ 44.4 (34.4–54.9)¶¶ 38.6 (34.2–43.2) 41.2 (39.7–42.8)
MCV4 ≤1 dose§§§ 39.7 (38.2–41.2) 43.1 (39.0–47.3) 46.8 (42.2–51.4)†† 47.3 (35.4–59.5)¶¶ 50.5 (40.3–60.8)¶¶ 40.8 (36.6–45.2) 42.0 (40.5–43.6)
HPV4¶¶¶
≥1 dose 35.0 (32.9–37.1) 35.7 (29.5–42.4) 44.4 (38.0–50.9)†† 52.8 (35.4–69.6)¶¶ 40.6 (27.6–55.2)¶¶ 46.4 (39.8–53.1)†† 35.8 (33.7–37.9)
≥3 doses 19.5 (17.8–21.3) 14.9 (9.7–22.3) 14.7 (11.4–18.8)†† — — 14.9 (9.6–22.2) 18.6 (17.0–20.3)
 * Adolescents (N = 17,835) in the 2008 NIS-Teen were born during January 1990–February 1996.
 † Respondents who self-identified as white, black, Asian, or American Indian/Alaska Native were all considered non-Hispanic. Persons who self-identified as Hispanic might be 
of any race. Native Hawaiian or other Pacific Islanders and persons of multiple races (n = 688) were not included because of small sample sizes.
 § Adolescents were classified as below poverty level if their total family income was less than the federal poverty level specified for the applicable family size and number of 
children aged <18 years. All others were classified as at or above the poverty level. Additional information available at http://www.census.gov/hhes/www/poverty.html. Poverty 
status was unknown for 744 adolescents.
 ¶ Confidence interval.
 ** Measles, mumps, and rubella vaccine.
 †† Statistically significant difference at p<0.05 in estimated vaccination coverage.  For race/ethnicity, referent group was white, non-Hispanic adolescents; for poverty status, 
referent group was at or above poverty level.
 §§ By parent/guardian report or provider records.
 ¶¶ Estimate might not be reliable; CI width >20. 
 *** Estimate not reported because unweighted sample size for the denominator was <30. 
 ††† Tetanus and diphtheria toxoids vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap), or tetanus-unknown type vaccine.
 §§§ Includes percentages receiving meningococcal conjugate vaccine (MCV4) or meningococcal-unknown type vaccine.
 ¶¶¶ Quadrivalent human papillomavirus vaccine. Percentages reported among females only (n = 8,607); HPV4 vaccine is not recommended for males.
 †† Additional information available at http://www2a.cdc.gov/nip/schoolsurv/
combinedlaws2007.pdf.
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recommended pediatric vaccines for all children.§§ Further 
evaluation of NIS-Teen data is needed to assess the impact 
state middle school requirements and vaccine-financing poli-
cies have on adolescent vaccination coverage.
Among vaccines routinely recommended for adolescents, 
coverage with ≥1 dose of HPV4, which was approved only 
2 years before the survey, had the greatest percentage-point 
increase (12.1) in vaccination coverage from 2007 to 2008. 
The percentage of females initiating the HPV4 series was 9.4 
percentage points higher among Hispanics compared with 
whites and 10.6 percentage points higher among those who live 
below the poverty level than those who live at or above the pov-
erty level. These findings are important because certain HPV 
infections are a major cause of cervical cancer and Hispanic 
adult females and those who live below the poverty level tend 
to have lower cervical cancer screening rates and higher rates 
of cervical cancer incidence and mortality (4). 
Why HPV4 vaccination coverage was higher among Hispanic 
adolescent females than whites was not clear. However, among 
survey participants, a much greater percentage of Hispanic 
adolescents were living below the poverty level (43.2%) than 
whites (6.7%). Higher coverage for the first dose of HPV4 
among adolescents living below the poverty level might be 
explained by vaccine financing concerns. Because HPV4 is 
the most expensive vaccine recommended for adolescents (6), 
its availability through the Vaccines for Children (VFC) pro-
gram has removed cost as a barrier to receiving HPV4 among 
VFC-eligible adolescents (i.e., adolescents who are uninsured, 
Medicaid eligible, or of American Indian/Alaska Native 
descent). Financial barriers to purchasing and administering 
HPV4 vaccine have been reported among private health-care 
providers (7), which might account for the lower coverage 
observed among adolescents who live at or above the poverty 
line and are more likely to be privately insured. Differences by 
poverty status were not observed for 3-dose HPV4 coverage; 
however, coverage overall was low (17.9%). Barriers other than 
cost might affect the ability of adolescent females to complete 
the HPV4 series, and further studies are needed to understand 
and address the barriers to receiving all of the recommended 
doses of HPV4.
The findings in this report are subject to at least four limita-
tions. First, NIS-Teen is a landline telephone survey; although 
studies indicate that statistical adjustments adequately com-
pensate for exclusion of households without telephones (8), 
sampling bias might remain. Second, underestimates of vac-
cination coverage might have resulted from the exclusive use 
of provider-verified vaccination histories because completeness 
of these records is unknown. Third, sample sizes were insuf-
ficient to adequately compare vaccine coverage rates among 
racial/ethnic groups stratified by poverty status. Finally, annual 
estimates for state and local areas and by racial/ethnic groups 
should be interpreted with caution because of smaller sample 
sizes and wider confidence intervals.
CDC will continue to monitor vaccination coverage among 
adolescents annually, enabling further analysis of coverage 
trends by race/ethnicity, poverty status, and geographic area. 
Results from a systematic review in 2000 identified several 
strategies shown to improve vaccination coverage among chil-
dren, adolescents, and adults, including 1) client and provider 
reminder, 2) vaccination requirements for school attendance, 
3) reduction of out-of-pocket costs, 4) increased vaccination 
access in health-care settings, and 5) assessment and feedback 
to vaccination providers (9). The majority of studies from 
which these efforts were identified targeted infant vaccination; 
therefore, additional research to identify evidence-based strat-
egies for improving vaccination coverage among adolescents 
specifically will be needed to achieve high coverage levels in 
this population.
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Update on Vaccine-Derived 
Polioviruses — Worldwide, 
January 2008–June 2009
In 1988, the World Health Assembly resolved to eradicate 
poliomyelitis worldwide (1). Subsequently, the Global Polio 
Eradication Initiative of the World Health Organization 
(WHO) reduced the global incidence of polio associated 
with wild polioviruses (WPVs) from an estimated 350,000 
cases in 125 countries in 1988 to 1,651 reported cases in 
2008 and reduced the number of countries that have never 
interrupted WPV transmission to four (Afghanistan, India, 
Nigeria, and Pakistan) (1). Under current WHO plans, when 
the goal of eradicating all WPV transmission is attained, oral 
poliovirus vaccine (OPV) use worldwide eventually will be 
discontinued. However, because vaccine-derived polioviruses 
(VDPVs) can produce polio outbreaks in areas with low 
rates of Sabin OPV coverage and can replicate for years in 
immunodeficient persons, enhanced strategies are needed to 
limit emergence of VDPVs (2). This report updates previous 
summaries (3,4) and describes VDPVs detected worldwide 
during January 2008–June 2009. During this period, 1) two 
new outbreaks of circulating VDPVs (cVDPVs) (accounting 
for 4–20 cases) were identified in the Democratic Republic 
of Congo and Ethiopia; 2) a previously identified outbreak in 
Nigeria ultimately resulted in a cumulative total of 292 cases; 
3) two newly identified paralyzed immunodeficient persons 
in Argentina and the United States were found to excrete 
VDPVs; and 4) isolated VDPVs were found among persons 
and environmental samples in 11 countries. All countries need 
to maintain 1) high rates of poliovirus vaccination coverage to 
prevent VDPV spread and 2) sensitive poliovirus surveillance 
to detect VDPVs.
Properties of VDPVs
VDPVs can cause paralytic polio in humans and have the 
potential for sustained circulation. VDPVs resemble WPVs 
biologically (2) and differ from most Sabin vaccine-related 
poliovirus (VRPV) isolates by having genetic properties con-
sistent with prolonged replication or transmission. Because 
poliovirus genomes evolve at a rate of approximately 1% per 
year, Sabin VRPV isolates that differ from the corresponding 
OPV strain by >1% of nucleotide positions (usually deter-
mined by sequencing the genomic region encoding the major 
viral surface protein, VP1) are estimated to have replicated 
for at least 1 year in one or more persons after administration 
of an OPV dose. This is substantially longer than the normal 
period of vaccine virus replication of 4–6 weeks in an OPV 
recipient.
Poliovirus isolates are divided into three serotypes: type 
1, type 2, and type 3. Isolates are divided further into three 
categories, based on the extent of VP1 nucleotide sequence 
divergence from the corresponding Sabin OPV strain: 1) Sabin 
VRPVs (≤1% divergent), 2) VDPVs (VRPVs that are >1% 
divergent from the corresponding Sabin strain), and 3) WPVs 
(no genetic evidence of derivation from any vaccine strain) 
(3). VDPVs are further categorized as 1) circulating VDPVs 
(cVDPVs), when evidence of person-to-person transmission in 
the community exists; 2) immunodeficiency-associated VDPVs 
(iVDPVs), which are isolated from persons with primary 
immunodeficiencies who have prolonged VDPV infections; 
and 3) ambiguous VDPVs (aVDPVs), which are either clinical 
isolates from persons with no known immunodeficiency or 
sewage isolates whose ultimate source is unknown (2).
Virologic Testing for VDPVs
Soon after the recognition of a cVDPV outbreak in Hispaniola 
in 2001 laboratories of the Global Polio Laboratory Network 
(GPLN) implemented a protocol to screen for VDPVs, using 
a combination of molecular and antigenic methods. VRPV 
isolates identified by molecular methods that had “non–
vaccine-like” antigenic properties were candidate VDPVs 
and were sequenced (2). However, since 2007, some VDPVs, 
especially less divergent type 2 VDPV (VDPV2) isolates, have 
undergone limited antigenic evolution and were missed by this 
screening protocol. A new method based on real-time reverse 
transcription–polymerase chain reaction (rRT-PCR), which 
targets nucleotide substitutions that occur early in VDPV 
emergence, has been evaluated and shown to detect VDPVs 
with much higher sensitivity and is being implemented as a 
routine screening method by GPLN as of 2009 (5).
cVDPVs
Democratic Republic of Congo. Retrospective and ongoing 
characterization of Sabin 2-related isolates by rRT-PCR found 
20 acute flaccid paralysis (AFP) cases associated with cVDPV2 
(1.1%–2.0% divergent) during 2005–2009 (Figure). Most 
(n = 15) cases occurred in Katanga Province during 2008–
2009, but others occurred in Bandundu (n = 2) in 2005, Sud-
Kivu (n = 1) in 2007, Orientale (n = 1) in 2007, and Kasai-
Occidental (n = 1) in 2008. The Katanga and Kasai-Occidental 
isolates had diverged into two main clusters of related lineages, 
whereas the remaining isolates were unlinked genetically. An 
additional 13 Sabin 2-related isolates with 0.6%–1.0% VP1 
divergence were found in Katanga and elsewhere, some of which 
clustered geographically and genetically with outbreak 
viruses.
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Ethiopia. Four closely-related cVDPV2 isolates (1.1%–1.2% 
divergent) were isolated during October 2008 and February 
2009 from AFP patients in East Harerghe.
Guinea. A girl aged 6 years, who had received 1 dose of 
OPV in 2003 and was living in a camp for refugees from 
Côte d’Ivoire, had AFP onset in May 2009. A VDPV2 (3.5% 
divergent) was isolated and was found to be closely related to 
several 2008–2009 cVDPV2 isolates from northern Nigeria.
Nigeria. Since 2005, 292 AFP cases associated with an 
outbreak of cVDPV2 have been reported in 11 northern and 
three central states of Nigeria. The outbreak is ongoing, with 
one case in 2005, 20 in 2006, 68 in 2007, 63 in 2008, and 
140 during January–June 2009. Twenty-eight percent (81 of 
292) of all cVDPV isolates were from Kano state, which has 
been a major reservoir for WPV type 1 (WPV1) and WPV3 
circulation within Nigeria (1,3). However, the proportion of 
cVDPV cases occurring outside of Kano increased to 81% 
during January 2008–June 2009. Genetic analysis of outbreak 
viruses indicated that the detected cases actually represent sev-
eral concurrent outbreaks arising from multiple independent 
cVDPV2 emergences during 2004–2006.
VDPV circulation was largely limited to the northern 
Nigerian states, where WPV1 and WPV3 circulation has 
continued (1). Two independent introductions of cVDPV2 
into the Republic of Niger from Nigeria were detected in 2006 
(3), and an introduction into Guinea was found in 2009. By 
comparison, WPV1 and WPV3 from Nigeria have spread 
widely in neighboring countries of Africa (6).
Of the 26 targeted supplementary immunization activi-
ties (SIAs)* conducted in Nigeria since 2006, 16 have used 
monovalent OPV type 1 (mOPV1), five have used mOPV3, 
and sixhave used trivalent OPV (tOPV) (most recently dur-
ing May 30–June 2, 2009 [as of June 30, 2009]). Routine 
immunization uses tOPV, but its use is estimated to be only 
61% nationwide and much lower in the northern states.
iVDPVs
Since the introduction of OPV in 1961, approximately 
40 persons with B-cell immunodeficiencies have been found 
FIGURE. Vaccine-derived polioviruses (VDPVs) detected worldwide, January 2008–June 2009
 * Immunodeficiency-associated VDPV.
 † Ambiguous VDPV.
 § Acute flaccid paralysis.
 ¶ Circulating VDPV.
 ** Spread of cVDPVs followed the elimination of the corresponding serotype of indigenous wild poliovirus, but with continued introduction of oral poliovirus 


























* Mass campaigns conducted during a short period (days to weeks) during which a 
dose of OPV is administered to all children aged <5 years, regardless of previous 
vaccination history. Campaigns can be conducted nationally or in portions of 
the country.
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to be excreting iVDPVs, which are indicative of prolonged 
infections. Currently, no effective therapies to clear iVDPV 
infections are available.
Argentina. A boy aged 15 months with x-linked agamma-
globulinemia, who had received three OPV doses in his first 
months of life, developed AFP in April 2009. iVDPV1 (3.6%–
3.8% divergent) was isolated from two serial stool specimens. 
No other VDPVs were detected among 87 contacts tested.
United States. OPV use in the United States ceased after 
1999.† In December 2008, a woman aged 44 years with a 
>20 year history of common-variable immunodeficiency 
developed ascending paralysis in all limbs and respiratory insuf-
ficiency. She died in March 2009 from various complications 
of her chronic illness, including neurologic sequelae. Highly 
divergent (12.3%) iVDPV2 was isolated from a pre-mortem 
stool specimen. A household member had received three OPV 
doses 13 years before onset of AFP in the decedent, and the 
estimated age of the iVDPV2 suggests that one of those doses 
could have been the source of exposure. This infection is inde-
pendent of the VDPV1 that circulated in an undervaccinated 
rural Minnesota community in 2005 (7).
aVDPVs
aVDPVs have been isolated in 11 countries during January 
2008–June 2009 (Table). Descriptions of the most divergent 
aVDPVs, all from sewage samples, follow.
Estonia. Highly divergent (approximately 15%) aVDPV2 
and aVDPV3 were isolated from separate sewage samples taken 
in September and December 2008. The isolates had sequence 
properties that suggested that they originated from a common 
infection, and the aVDPV3 is related to another Estonian 
aVDPV3 isolated from sewage described previously (2,8).
Finland. Highly divergent (approximately 15%) aVDPV1, 
aVDPV2, and aVDPV3 were isolated from sewage samples 
collected in Tampere in December 2008 and June 2009. 
The isolates had sequence properties that suggested that they 
originated from a common infection. The Finnish aVDPVs 
are distinct from the Estonian aVDPVs.
Israel. Environmental monitoring for polioviruses was 
implemented by Israel after its 1987–1988 WPV1 outbreak. 
Monitoring sewage samples from the Tel Aviv area (sam-
pling populations of approximately 350,000 and 10,000) 
yielded two groups of type 2 aVDPVs (9). The first group 
was detected initially in 1998, and 19 more highly divergent 
representatives (approximately 15% divergent) were detected 
during 2008–2009. The second group, detected since 2006, is 
less divergent (approximately 7%) and is defined by 10 isolates. 
Despite follow-up investigations, no source for these VDPVs 
has been identified. An aVDPV1 (8.2% divergent) was isolated 
from an environmental sample collected from a site sampling 
a different population in Haifa on February 22, 2009.
Reported by: Polio Eradication Dept, World Health Organization, 
Geneva, Switzerland. Div of Viral Diseases, Global Immunization Div, 
National Center for Immunization and Respiratory Diseases, CDC.
Editorial Note: The recent VDPV emergences reinforce 
some key lessons for the Global Polio Eradication Initiative. 
The cVDPV2 outbreak in Nigeria, whose 4-year duration 
is surpassed only by the decade-long cVDPV2 outbreak in 
Egypt during 1983–1993 (10), further demonstrates that 
cVDPVs, like WPV, can circulate indefinitely in settings with 
low rates of poliovirus vaccination coverage. The emergence 
of multiple independent cVDPV2 lineages in Nigeria and the 
unrelated cVDPV2 outbreaks in the Democratic Republic of 
Congo and Ethiopia highlight the particular risks for emer-
gence of cVDPV2 in settings of low tOPV coverage (10). 
Improvements in laboratory methods for the identification 
of VDPV2 facilitated early detection of the outbreaks in the 
Democratic Republic of Congo and Ethiopia, but maintenance 
of sensitive AFP surveillance was crucial; any temporal and 
geographic clustering of vaccine-related isolates of the same 
serotype should prompt further investigation.
The appearance of an iVDPV case in the United States 13 
years after the likely exposure and 9 years after cessation of 
OPV use illustrates the continued risk among immunodeficient 
persons from past OPV use. Chronic iVDPV excretors (i.e., 
excretion for >5 years) have been described in several countries 
that have shifted to inactivated poliovirus vaccine (IPV) (2), 
and the highly divergent aVDPVs found in sewage in Israel, 
Estonia, and Finland have similar genetic properties to iVDPVs 
from chronic excretors. The appearance of an iVDPV case in 
Argentina further underscores the risks of prolonged iVDPV 
excretion in middle-income countries (2,3).
Several of the aVDPVs described in this report show only 
limited divergence (1.1%–1.5%) and were detected after 
implementation of the new rRT-PCR screening methods. In 
some settings such isolates are observed sporadically, and no 
genetically linked VDPVs are found subsequently. However, 
in settings of potential low local tOPV coverage, the sporadic 
detection of aVDPVs should prompt further clinical investi-
gation (when the patient is identified), review of surveillance 
and polio vaccination coverage data, and implementation of † Additional information available at http://www.cdc.gov/mmwr/preview/
mmwrhtml/rr4905a1.htm.
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cVDPV†† Nigeria§§ 2005–2009 Outbreak 
(292 cases)¶¶
2 292 — — 1.0–5.1 61 5 yrs June 27, 2009
Guinea 2009 Importation 
(1 case)***






2 33 — — 1.0–2.0 68 4 yrs March 7, 2009
Ethiopia 2008–2009 Outbreak 
(4 cases)
2 4 — — 1.2 75 1 yr February 16, 2009
iVDPV††† Argentina 2009 AFP§§§ patient 
(XLA¶¶¶)
1 1 — 2 3.6–3.8 94 ≥15 mos Alive (April 23, 2009)
United States 2009 AFP patient 
(CVID****)
2 1 — — 12.3 96 (IPV††††) 13 yrs Died in March 2009
aVDPV§§§§ Angola 2008 AFP patient 2 1 — — 1.1 75 1 yr May 5, 2008
2008 AFP patient 2 1 — — 1.1 1 yr May 25, 2008
China 2009 AFP patient 2 1 — — 1.2 99 1 yr February 22, 2009
Egypt 2008 Environment 2 — 1 1.7 97 1.5 yrs April 7, 2008
Estonia 2008 Environment 2 — — 1 14.5 95 >15 yrs September 25, 2008
2008 Environment 3 — 1 15.6 >15 yrs December 29, 2008
Ethiopia 2009 AFP patient 3 1 — — 1.3 75 1 yr April 30, 2009
Finland 2008–2009 Environment 1 — — 1¶¶¶¶ 12.4 97 (IPV) 13 yrs December 15, 2008
2008–2009 Environment 2 — — 1 12.7 13 yrs December 15, 2008
2009 Environment 3 — — 1 14.6 14 yrs June 26, 2009
India 2009 AFP patient 1 1 — — 1.1 66 1 yr April 7, 2009
2009 AFP patient 2 1 — — 1.3 1 yr April 30, 2009
2009 AFP patient 2 1 — — 1.1 1 yr June 29, 2009
2009 Environment 3 — — 1 1.2 1 yr May 20, 2009
Israel 2009 Environment 1 — — 1 8.2 95 (IPV) 8 yrs February 22, 2009
1998–2009 Environment 2 — — 33***** 8.8–15.3 >15 yrs January 20, 2009
2006–2009 Environment 2 — — 10***** 6.6–9.7 10 yrs November 25, 2008
Malawi 2008††††† AFP patient 3 1 — — 3.1 92 3 yrs January 14, 2008
Russia 2008 Healthy child 1 1 — — 1.4 98 (IPV) 1 yr Alive (March 2008)
Somalia 2008 AFP patient 2 1 — — 1.1 24 1 yr April 5, 2008
2008 AFP patient 2 1 1 — 1.6 1 yr June 24, 2008
Switzerland 2008 Environment 2 — — 1 1.2 95 (IPV) 1 yr January 2008
2008 Environment 1 — — 1 1.1 1 yr March 2008
 * Total years detected and cumulative totals for the previously reported cVDPV outbreak (Nigeria).
 † Includes environmental aVDPV isolates (Israel).
 § Oral poliovirus vaccine.
 ¶ Based on 2008 data from the World Health Organization (WHO) Vaccine Preventable Diseases Monitoring System (2009 global summary) and WHO-UNICEF coverage 
estimates, available at http://www.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm. National data might not reflect weaknesses at subnational 
levels.
 ** Duration of cVDPV circulation was estimated from extent of VP1 nucleotide divergence from the corresponding Sabin OPV strain; duration of immunodeficiency-associated 
VDPV replication was estimated from clinical record by assuming that exposure was from initial receipt of OPV; duration of ambiguous VDPV replication was estimated from 
sequence data.
 †† Circulating VDPV. Most cVDPV isolates from Nigeria, Democratic Republic of Congo, Ethiopia, and Guinea were vaccine/nonvaccine recombinants.
 §§ Previously reported outbreak; OPV coverage <50% around cases.
 ¶¶ Excludes isolates 0.5%–1.0% divergent from Sabin 2 that are closely related to the cVDPV isolates: 16 from Nigeria and 13 from Democratic Republic of Congo. Some of 
the isolates formed genetic lineages.
 *** Importation from Nigerian cVDPV outbreak. Isolate shared >60% of nucleotide differences from Sabin 2 with cVDPV isolates from northern Nigeria.
 ††† Immunodeficiency-associated VDPV. None of the iVDPV isolates appeared to be vaccine/nonvaccine recombinants.
 §§§ Acute flaccid paralysis.
 ¶¶¶ X-linked agammaglobulinemia.
 **** Common variable immunodeficiency.
 †††† Inactivated poliovirus vaccine.
 §§§§ Ambiguous VDPV. None of the aVDPV isolates appeared to be vaccine/nonvaccine recombinants.
 ¶¶¶¶ Types 1 and 2 aVDPVs were isolated from the same environmental sample.
 ***** Two separate lineages of type 2 aVDPVs were isolated from environmental samples in Israel.
 ††††† AFP onset on December 23, 2007.
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vaccination campaigns (mop-ups and SIAs, usually with tOPV) 
to prevent virus spread.
Experience has underscored the importance of routine 
immunization either with IPV or tOPV to prevent VDPV 
spread (10). In countries with low rates of routine vaccination, 
closing the immunity gaps to all three poliovirus serotypes 
by periodic but regular use of tOPV in SIAs is important. 
However, high rates of tOPV coverage will not prevent or clear 
VDPV infections in immunodeficient hosts. WHO, in collabo-
ration with other partners, is exploring antiviral compounds 
for their potential to clear iVDPV infections (3).
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Updated Recommendations 
from the Advisory Committee 
on Immunization Practices (ACIP) 
for Use of Hepatitis A Vaccine 
in Close Contacts of Newly 
Arriving International Adoptees
On February 25, 2009, the Advisory Committee on 
Immunization Practices (ACIP) recommended routine hepa-
titis A vaccination for household members and other close 
personal contacts (e.g., regular babysitters) of adopted children 
newly arriving from countries with high or intermediate hepa-
titis A endemicity. This new recommendation complements 
previous ACIP recommendations for hepatitis A vaccination 
for persons traveling from the United States to countries with 
high or intermediate hepatitis A endemicity (1,2) (including 
persons with travel related to international adoption), and 
postexposure prophylaxis for contacts of persons with hepa-
titis A (1). This report introduces the new recommendation 
and outlines the underlying epidemiologic and programmatic 
rationale.
Rationale and Methods
Hepatitis A virus (HAV) can produce either asymptomatic 
or symptomatic infection in humans after an average incuba-
tion period of 28 days (range: 15–50 days) (3). Peak infectiv-
ity occurs during the 2-week period before onset of jaundice 
or elevation of liver enzymes, when concentration of virus in 
stool is highest (4). Illness caused by HAV typically has an 
abrupt onset that can include fever, malaise, anorexia, nausea, 
abdominal discomfort, dark urine, and jaundice. The likeli-
hood of having symptoms with HAV infection increases with 
age. Fewer than 10% of infections among children aged 0–4 
years result in jaundice; this percentage increases to 30%–40% 
among children aged 5–9 years, 60%–80% among youths 
aged 10–17 years, and 80%–90% among adults aged ≥18 
years (5). When signs and symptoms occur, typically they last 
<2 months, although 10%–15% of symptomatic persons have 
prolonged or relapsing disease lasting up to 6 months (6). The 
case-fatality rate for HAV infection increases with age: 1.8% 
for persons adults aged >50 years compared with 0.6% for 
persons aged <50 years. The case-fatality rate is also increased 
among persons with chronic liver disease, who are at increased 
risk for acute liver failure (7).
In making its recommendation, ACIP considered the like-
lihood that a child adopted by parents in the United States 
might be actively infected with HAV and shedding virus at 
the time of adoption. During 1998–2008, approximately 
18,000 children (range: 15,583 to 22,884) were adopted from 
foreign countries by families in the United States each year.* 
Approximately 99.8% of these children came from countries 
where hepatitis A is considered to be of high or intermediate 
endemicity (2), and approximately 85% of were aged <5 years. 
Country-specific policies pertaining to foreign adoption are 
changing constantly, leading to rapid changes in the numbers 
of international adoptees entering the United States from vari-
ous countries. Although South Korea was the most common 
country of origin for adoptions in the United States in the early 
1990s, Russia and China became prominent in international 
adoption in the late 1990s, and currently the largest numbers 
* Additional information available at http://adoption.state.gov/news/total_chart.
html.
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of adopted children come from Guatemala, China, Russia, and 
Ethiopia. The incidence of HAV infection is highest in these 
countries among children aged <5 years, when HAV infection 
is likely to be asymptomatic.
ACIP also considered recent reports of HAV infection among 
persons in close contact with new adoptees from countries of 
high or intermediate hepatitis A endemicity. Such persons are 
at greater risk for HAV infection. In 2007, CDC was notified 
of a case of fulminant hepatitis A in a nontraveling household 
contact of an asymptomatic Ethiopian adoptee confirmed to 
have acute hepatitis A (immunoglobulin M [IgM] antibody 
to HAV [anti-HAV] positive). This case prompted further 
investigation that led to identification of 20 other cases of acute 
hepatitis A among persons who had close personal contact with 
newly arriving internationally adopted children and no history 
of traveling abroad (8). Two acute hepatitis A cases were iden-
tified among traveling parents who had not been vaccinated. 
This same study found that 98% of parents traveling to pick 
up their children had been vaccinated against hepatitis A in 
accordance with existing ACIP recommendations (8).
Since 2007, CDC has received 14 additional reports of 
acute hepatitis A following exposure to nonjaundiced adoptees 
newly arriving from countries of high or intermediate hepatitis 
A endemicity. Although these numbers are small compared 
with the total number of hepatitis A cases (2,979) reported to 
CDC in 2007 (9), they likely represent an underestimate of 
the number of hepatitis A cases associated with international 
adoptions because contact with an international adoptee is not 
asked routinely as part of national hepatitis A surveillance. All 
of the 14 adoptee-associated cases identified since 2007 were 
in close contacts who had not been vaccinated against hepatitis 
A and had no history of travel and no other risk factors for 
hepatitis A. In one instance, both adoptive parents developed 
hepatitis A that required hospitalization (CDC, unpublished 
data, 2008). In another instance, a 2008 community outbreak 
with 12 hepatitis A cases was associated with an asymptomatic 
HAV-infected international adoptee; two infected contacts were 
hospitalized, and disease was identified among tertiary contacts 
in an elementary school (CDC, unpublished data, 2009).
Data from a study conducted at three adoption clinics in the 
United States, each screening 100–200 incoming adoptees for 
hepatitis A each year, indicate that 1%–6% of newly arrived 
international adoptees are acutely infected with HAV (non-
jaundiced; IgM anti-HAV positive). A proportion of these 
adoptees represent a source of infection for susceptible close 
contacts (9). The risk for hepatitis A among close personal 
contacts of international adoptees is estimated at 106 (range: 
90–819) per 100,000 household contacts of international 
adoptees within the first 60 days of their arrival in the United 
States (CDC, unpublished data, 2009). By comparison, accord-
ing to surveillance data, the estimated rate of symptomatic 
hepatitis A in the U.S. general population in 2007 was 1.0 
per 100,000 population (10).
Updated Recommendation
Based on this evidence, on February 25, ACIP updated its 
guidance by recommending hepatitis A vaccination for all 
previously unvaccinated persons who anticipate close personal 
contact (e.g., household contact or regular babysitting) with 
an international adoptee from a country of high or interme-
diate endemicity during the first 60 days following arrival of 
the adoptee in the United States. The first dose of the 2-dose 
hepatitis A vaccine series should be administered as soon as 
adoption is planned, ideally 2 or more weeks before the arrival 
of the adoptee.
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Licensure of a Haemophilus 
influenzae Type b (Hib) 
Vaccine (Hiberix) and Updated 
Recommendations for Use 
of Hib Vaccine
On August 19, 2009, the Food and Drug Administration 
(FDA) licensed Hiberix (GlaxoSmithKline Biologicals, 
Rixensart, Belgium), a Haemophilus influenzae type b (Hib) 
conjugate vaccine composed of H. influenzae type b capsular 
polysaccharide (polyribosyl-ribitol-phosphate [PRP]) conju-
gated to inactivated tetanus toxoid (PRP-T). Hiberix is licensed 
for use as the booster (final) dose of the Hib vaccine series 
for children aged 15 months through 4 years (before the 5th 
birthday) who have received previously the primary series of 
Hib vaccination (consisting of 2 or 3 doses, depending on the 
formulation) (1). The Advisory Committee on Immunization 
Practices (ACIP) recommends Hib booster vaccination for 
children at ages 12 through 15 months; however, because of the 
recent shortage of Hib vaccines, many children have deferred 
the booster dose and therefore require catch-up vaccination 
(2). This report summarizes the indications for Hiberix use 
and provides guidance on Hib booster dose administration 
based on increasing vaccine supplies. Vaccination recommen-
dations in this report update the previous advisory on Hib 
booster administration (June 26, 2009) (2), which advised 
that children with deferred booster doses receive it at the next 
regularly scheduled visit. Vaccination providers are now rec-
ommended to begin recall of children in need of the booster 
dose when feasible and monovalent Hib vaccine supply in the 
office is adequate.
Hiberix Licensure
FDA licensed the new vaccine after review of safety and 
immunogenicity data from seven core studies conducted outside 
the United States that evaluated Hiberix for the booster dose 
in 1,008 children (3,4). The children in these studies received 
various Hib conjugate vaccines for the primary series, including 
Hiberix (not approved for primary series in the United States), 
and the monovalent Hib vaccines currently licensed for primary 
series in the United States, ActHIB (PRP-T, Sanofi Pasteur, 
Swiftwater, Pennsylvania) and PedvaxHIB (PRP-OMP, Merck 
& Co., Inc., West Point, Pennsylvania). In the seven core stud-
ies, Hiberix was given concomitantly with one of the following 
vaccines (all non-U.S. formulations, not licensed in the United 
States; GlaxoSmithKline Biologicals): diphtheria, tetanus, and 
acellular pertussis vaccine (DTaP), DTaP-hepatitis B vaccine 
(DTaP-HBV), DTaP-HBV-inactivated polio vaccine (DTaP-
HBV-IPV), or DTaP-inactivated polio vaccine (DTaP-IPV). 
Serologic endpoints showed that the booster dose of Hiberix 
provided levels of antibodies protective against Hib invasive 
disease. Rates of adverse events generally were comparable to 
those observed with other childhood vaccines. In one of the 
core studies with 371 children, the frequencies of solicited local 
symptoms (i.e., redness, pain, or swelling) were each less than 
25% (3), comparable to that reported in studies of currently 
licensed monovalent Hib conjugate vaccines (1). Hiberix was 
first introduced to markets outside the United States in 1996 
and is used in nearly 100 countries (3,4).
Hiberix is supplied as a lyophilized powder for reconstitution 
in sterile 0.9% saline solution (3). Each 0.5 mL intramuscular 
dose of Hiberix contains 10 µg of purified H. influenzae type b 
capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]) 
conjugated to inactivated tetanus toxoid (PRP-T) (3). Hiberix 
does not contain thimerosal (3).
Indications and Guidance for Use
Hiberix is licensed for use as the booster (final) dose for 
Hib vaccination for children aged 15 months through 4 years 
(before the 5th birthday) who have received a primary Hib 
vaccination series of 2 or 3 doses (depending on the formula-
tion of the primary series vaccines). ACIP recommends Hib 
booster dosing at ages 12 through 15 months (1). To facilitate 
timely booster vaccination, Hiberix and other Hib conjugate 
vaccines can be administered as early as age 12 months, in 
accordance with Hib vaccination schedules for routine and 
catch-up immunization (5). Hiberix is not licensed for the 
primary Hib vaccination series; however, if Hiberix is admin-
istered inadvertently during the primary vaccination series, 
the dose should be counted as a valid PRP-T dose that does 
not need to be repeated if it was administered according to 
schedule (5). In these children, a total of 3 doses will complete 
the routine primary series.
Children aged 12 months through 4 years (before the fifth 
birthday) who did not receive a booster because of the recent 
shortage of Hib vaccines should receive a booster with any of 
the available Hib-containing vaccines at the earliest opportu-
nity (2). With licensure of Hiberix and anticipated distribu-
tion, the increased supply of Hib-containing vaccines will be 
sufficient to support a provider-initiated notification process 
to contact all children whose Hib booster dose had been 
deferred. When feasible and when vaccine supply in the office 
is sufficient, vaccination providers should review electronic or 
paper medical records or immunization information system 
(e.g., registry) records to identify and recall children in need of 
a booster dose. If supplies are not adequate, providers should 
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continue to follow previous recommendations to provide the 
booster dose at the child’s next regularly scheduled visit (2).
Information Regarding Supply 
of Hiberix, ActHib, and Pentacel
At this time, production of Merck Hib vaccine products 
remains suspended; however, supplies of Sanofi Pasteur vac-
cines ActHIB (monovalent Hib vaccine) and Pentacel (DTaP-
IPV/Hib) are available for use for the primary Hib vaccination 
series and booster in infants and children. Vaccination pro-
viders with questions about supplies of Hiberix monovalent 
Hib vaccine purchased with nonpublic funds should contact 
GlaxoSmithKline Biologicals’ customer service department 
(telephone, 866-475-8222). Providers with questions about 
supplies of ActHIB or Pentacel purchased with nonpub-
lic funds should contact Sanofi Pasteur’s customer service 
department (telephone, 800-822-2463). For public vaccine 
supplies, including Vaccines for Children Program vaccine, 
providers should contact their state/local immunization pro-
gram to obtain vaccine. Providers ordering Hiberix through 
the Vaccines for Children Program may place orders in early 
October.
This recommendation reflects CDC’s assessment of the 
existing national Hib vaccine supply and will be updated if 
the supply changes. Updated information about the national 
Hib vaccine supply is available at http://www.cdc.gov/vaccines/
vac-gen/shortages/default.htm. Details about the routine Hib 
vaccination schedule are available at http://www.cdc.gov/
vaccines/recs/schedules/default.htm#child. Adverse events 
after receipt of any vaccine should be reported to the Vaccine 
Adverse Event Reporting System at http://vaers.hhs.gov.
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Update: Influenza Activity — 
United States, April–August 2009
On September 10, this report was posted as an MMWR Early 
Release on the MMWR website (http://www.cdc.gov/mmwr).
The first 2009 pandemic influenza A (H1N1) virus infec-
tions were identified in the United States in April 2009 (1). 
By August, the cumulative number of infections in the United 
States was estimated to be at least 1 million.* This report pro-
vides an overview of influenza activity during April–August 
2009 and recommendations for the upcoming 2009–10 influ-
enza season. Pandemic H1N1 influenza activity peaked in the 
United States during May and June and declined during July 
and early August. However, levels of influenza activity remained 
above normal for summer months, and focal outbreaks were 
reported throughout the summer. During the last 2 weeks of 
August, pandemic H1N1 influenza activity increased in certain 
areas of the United States. Clinicians and public health officials 
should be aware that these recent increases might signal an early 
start to the 2009–10 influenza season, with pandemic H1N1 
influenza viruses predominating at least initially.
In the United States, CDC’s National Influenza Surveillance 
System consists of nine different systems that monitor influenza 
viruses and the geographic spread and level of influenza activ-
ity. In addition to these ongoing systems, in April 2009, in 
response to the emergence and spread of the pandemic H1N1 
virus, the states and CDC implemented line-listed reporting for 
cases of pandemic H1N1. In May, this system transitioned to 
include aggregate counts of pandemic H1N1 influenza cases, 
hospitalizations, and deaths. On July 24, CDC recommended 
that states discontinue reporting of individual confirmed and 
probable cases of pandemic H1N1 virus infection but to 
continue to provide aggregate reports of influenza-associated 
hospitalizations and deaths. From mid-April to August 30, a 
total of 9,079 hospitalizations and 593 deaths associated with 
laboratory-confirmed 2009 pandemic influenza A (H1N1) 
virus infections were reported to CDC.
World Health Organization and National Respiratory and 
Enteric Virus Surveillance System collaborating laboratories 
located in all 50 states and the District of Columbia report to 
CDC the number of respiratory specimens tested for influ-
enza and the number positive by influenza type and subtype. 
Since May 3, the majority of influenza viruses identified have 
been pandemic H1N1 influenza A viruses. As of September 
4, all of the influenza A H1N1 viruses characterized at 
CDC have been related antigenically to the reference strain 
chosen for the influenza A (H1N1) monovalent vaccine: 
A/California/7/2009(H1N1)pdm. Of 1,372 pandemic H1N1 
* Additional information available at http://www.cdc.gov/h1n1flu/surveillanceqa.
htm.
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viruses tested for antiviral resistance at CDC from ill persons in 
the United States, 1,364 (99.4%) have been susceptible to osel-
tamivir. All eight pandemic H1N1 viruses found to be resistant 
to oseltamivir were obtained from persons taking oseltamivir 
for treatment or prophylaxis at the time of specimen collection. 
All viruses tested have been susceptible to zanamivir, and all 
have been resistant to amantadine and rimantadine.
Outpatient visits to health-care providers for influenza-
like illness (ILI) are monitored in the United States through 
the Outpatient Influenza-like Illness Surveillance Network 
(ILINet). Visits to health-care providers were highest in 
February during the 2008–09 influenza season, but rose again 
in May 2009 after the 2009 H1N1 virus emerged (Figure 1). 
Visits to health-care providers for ILI were higher than usual in 
the summer and increased during the last 2 weeks of August. 
During that period, the proportion of outpatient visits for 
ILI in Department of Health and Human Services Region 
IV (Alabama, Florida, Georgia, Kentucky, Mississippi, North 
Carolina, South Carolina, and Tennessee) increased to a level 
usually seen only during peak winter periods.
Laboratory-confirmed influenza-associated hospitalizations 
are monitored in two population-based surveillance networks: 
the New Vaccine Surveillance Network and the Emerging 
Infections Program. Total influenza hospitalization rates by age 
group for adults and children during April–August generally 
were similar to or lower than seasonal influenza hospitalization 
rates but were higher than usual for that period. (Figure 2).
Data from the 122 Cities Mortality Reporting System indi-
cate that the proportion of deaths attributed to pneumonia and 
influenza was within the bounds of what is expected in the sum-
mer and did not exceed the epidemic threshold for 2 or more 
consecutive weeks at any time during April–August. However, 
47 pediatric deaths associated with laboratory-confirmed pan-
demic H1N1 influenza occurred during April 26– August 29 
and were reported to CDC.
Six states (Alabama, Alaska, Florida, Georgia, Mississippi, and 
South Carolina) and Puerto Rico reported widespread influenza 
activity for the most recent reporting week (August 23–29) 
(Figure 3). Any widespread influenza activity in August is 
uncommon. Thirteen additional states reported regional 
influenza activity.
Reported by: L Finelli, DrPH, L Brammer, MPH, L Blanton, MPH, 
S Epperson, MPH, R Dhara, MPH, A Fowlkes, MPH, D Mustaquim, 
MPH, L Kamimoto, MD, K Kniss, MPH, A Klimov, PhD, L Gubareva, 
PhD, A Fry, MD, A Fiore, MD, D Jernigan, MD, J Bresee, MD, 
Influenza Div; D Swerdlow, MD, National Center for Immunization 
and Respiratory Diseases, CDC.
* The national baseline is the mean percentage of visits for ILI during noninfluenza weeks for the previous three seasons plus two standard deviations. A non-
influenza week is a week during which <10% of specimens tested positive for influenza. Use of the national baseline for regional data is not appropriate.
FIGURE 1. Percentage of visits for influenza-like illness (ILI) reported by the U.S. Outpatient Influenza-like Illness Surveillance 
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Editorial Note: Influenza activity during April–August 2009 
was higher than expected for this period in all surveillance 
systems except for the 122 Cities Mortality Reporting System, 
and 2009 pandemic influenza A (H1N1) virus has continued 
to circulate as the predominant influenza virus. During the 
last 2 weeks of August, influenza activity increased in the 
southeastern United States to levels of ILI usually seen during 
winter seasonal influenza peaks. This increase might signal that 
other areas of the country also will have early influenza activity 
during the 2009–10 influenza season. Physicians, businesses, 
schools, and others are reminded that the timing and severity 
of influenza activity can be unpredictable, but that increased 
influenza activity resulting from pandemic H1N1, in addition 
to the usual seasonal influenza viruses, is expected this season. 
Changes in geographic spread of the virus will be monitored 
and reported weekly in the online FluView report.† Regular 
updates will be published in MMWR during the season as 
well. Additional guidance for this influenza season also is 
available online.§
* Age group–specific average influenza rate, October–April, 2005–06, 
2006–07, and 2007–08 influenza seasons.
FIGURE 2. Laboratory-confirmed influenza hospitalization 
rates per 10,000 population, by age group and surveillance 
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* Levels of activity are 1) no activity; 2) sporadic: isolated laboratory- 
confirmed influenza cases or a laboratory-confirmed outbreak in one 
institution, with no increase in activity; 3) local: increased influenza-like 
illness (ILI), or at least two institutional outbreaks (ILI or laboratory- 
confirmed influenza) in one region with recent laboratory evidence of 
influenza in that region (virus activity no greater than sporadic in other 
regions); 4) regional: increased ILI activity or institutional outbreaks (ILI 
or laboratory-confirmed influenza) in at least two but less than half of the 
regions in the state with recent laboratory evidence of influenza in those 
regions; and 5) widespread: increased ILI activity or institutional outbreaks 
(ILI or laboratory-confirmed influenza) in at least half the regions in the 
state with recent laboratory evidence of influenza in the state.
FIGURE 3. Estimated influenza activity levels reported by state 
epidemiologists, by level of activity — United States, week 








† Available at http://www.cdc.gov/flu/weekly.
§ Available at http://www.cdc.gov/h1n1flu.
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CDC recently issued updated guidance to schools, universi-
ties, child care and early education programs, and businesses 
regarding methods to limit the spread of influenza in each of 
these settings (2–4). These guidance documents stress actions 
that will limit exposure to potentially infectious persons, 
such as the recommendation to stay home when ill and the 
separation of ill persons from well persons. CDC also updated 
recommendations for the amount of time a person with ILI 
should remain at home and away from school and work (5). 
CDC currently recommends that persons with ILI stay home 
for 24 hours after they are free from fever (100°F[37.8°C]) 
without taking fever-reducing medications. In addition, strict 
adherence to respiratory etiquette and hand hygiene should 
be stressed in school and work settings and in other settings 
where close contact between persons can occur.
Updated guidance on the use of influenza antiviral medica-
tions was issued by CDC on September 8 (6). Early treatment 
of all persons with severe illness from suspected or confirmed 
influenza, including those who are hospitalized, is recom-
mended. In addition, this guidance recommends the early 
evaluation and treatment of persons with suspected influenza 
who are at greater risk for influenza-associated complications.¶ 
However, most healthy children, adolescents, and adults with 
uncomplicated influenza-like illness do not require antiviral 
treatment. Approximately 97% of all influenza viruses currently 
circulating in the United States are pandemic H1N1 viruses 
that are sensitive to oseltamivir or zanamivir. Thus, CDC 
recommends either oseltamivir or zanamivir for treatment or 
chemoprophylaxis for influenza when use of antiviral medica-
tions is indicated. Clinical judgment always is an important 
component of treatment decision-making for persons who 
present with suspected influenza. When treatment is given, 
efforts to ensure that treatment is started as early as possible 
after symptom onset are critical.
The best means to prevent influenza illness is vaccination. 
CDC continues to recommend vaccination against seasonal 
influenza viruses, especially for all children, persons aged 
≥50 years, and persons at greater risk for influenza compli-
cations (7). Seasonal influenza vaccines are widely available 
now. Vaccines against the pandemic H1N1 influenza virus 
are expected to be available by mid-October and will be 
administered as separate vaccinations. The pandemic H1N1 
monovalent vaccine is being prepared by the same manufac-
turers as the seasonal influenza vaccine. Many persons will be 
recommended to receive both the seasonal influenza vaccine 
and the pandemic H1N1 vaccine. During the early phase of 
vaccine availability, the number of pandemic H1N1 vaccine 
doses will not be enough to vaccinate the entire U.S. popula-
tion. The Advisory Committee on Immunization Safety has 
recommended that immunization programs focus initially 
on providing protection for persons who are at greater risk 
for infection or influenza complications, including pregnant 
women, household contacts and caregivers for children aged 
<6 months, health-care and emergency medical services per-
sonnel, all persons aged 6 months–24 years, and persons aged 
25–64 years who have health conditions associated with greater 
risk for medical complications from influenza (8).
The Council of State and Territorial Epidemiologists and 
CDC have developed new case definitions for aggregate report-
ing of influenza-associated hospitalizations and deaths for the 
2009–10 influenza season. These new case definitions will be 
implemented for the week ending September 5 (surveillance 
week 35). For aggregate reporting purposes, the 2008–09 
influenza season was closed out on August 30; the total aggre-
gate numbers of hospitalizations and deaths associated with 
pandemic H1N1 were reported on September 4. The first 
week of reporting influenza-associated hospitalizations and 
deaths for the 2009–10 season will include both seasonal and 
pandemic H1N1–associated hospitalizations and deaths, and 
will be reported on September 11.
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QuickStats
from the national center for health statistics
Percentage of Adults Aged ≥18 Years Who Have Ever Had An Oral 
Cancer Examination,* by Smoking Status and Age Group† — 
National Health Interview Survey, United States, 2008§
* Based on affirmative responses to either of the following questions: “Have you 
ever had an exam for oral cancer in which the doctor, dentist, or other health 
professional pulls on your tongue, sometimes with gauze wrapped around it, 
and feels under the tongue and inside the cheeks?” or “Have you ever had an 
exam for oral cancer in which the doctor, dentist, or other health professional 
feels your neck?”
† Based on responses to the following questions: “Have you smoked at least 
100 cigarettes in your entire life?” and “Do you now smoke cigarettes every 
day, some days, or not at all?” Lifetime smoking status was defined as follows: 
Never smoker (never smoked at all or smoked less than 100 cigarettes in 
lifetime); former smoker (smoked at least 100 cigarettes in lifetime but not 
currently smoking); and current smoker (smoked at least 100 cigarettes in 
lifetime and currently smoking).
§ Estimates are based on household interviews of a sample of the civilian, 
noninstitutionalized U.S. population.
¶ 95% confidence interval.
In 2008, 29.4% of adults aged ≥18 years had ever had an oral cancer examination in which a doctor, 
dentist, or other health professional pulled on their tongue or palpated their neck. Adults aged ≥40 years 
were more likely to have ever had an examination than those aged 18–39 years, regardless of smoking 
status. Those most at risk for oral cancer (current smokers aged ≥40 years) were less likely to have ever 
had an oral cancer examination than former smokers or never smokers.
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, 









Total cases reported 
for previous years States reporting cases
during current week (No.)2008 2007 2006 2005 2004
Anthrax — — 0 — 1 1 — —
Botulism:
 foodborne — 12 1 17 32 20 19 16
 infant — 33 2 109 85 97 85 87
 other (wound and unspecified) — 17 1 19 27 48 31 30
Brucellosis 2 67 2 80 131 121 120 114 CA (2)
Chancroid 2 20 0 25 23 33 17 30 NY (2)
Cholera — 4 0 5 7 9 8 6
Cyclosporiasis§ 1 105 2 139 93 137 543 160 FL (1)
Diphtheria — — — — — — — —
Domestic arboviral diseases§,¶:
 California serogroup — 16 5 62 55 67 80 112
 eastern equine — 3 1 4 4 8 21 6
 Powassan — 1 0 2 7 1 1 1
 St. Louis — 7 1 13 9 10 13 12
 western equine — — — — — — — —
Ehrlichiosis/Anaplasmosis§,**:
 Ehrlichia chaffeensis 4 489 19 1,137 828 578 506 338 NY (2), DE (1), TN (1)
 Ehrlichia ewingii — 4 0 9 — — — —
 Anaplasma phagocytophilum 5 355 17 1,026 834 646 786 537 NY (5)
 undetermined — 79 4 180 337 231 112 59
Haemophilus influenzae,†† 
invasive disease (age <5 yrs):
 serotype b — 16 0 30 22 29 9 19
 nonserotype b 1 141 2 244 199 175 135 135 OK (1)
 unknown serotype — 170 2 163 180 179 217 177
Hansen disease§ — 45 2 80 101 66 87 105
Hantavirus pulmonary syndrome§ — 6 1 18 32 40 26 24
Hemolytic uremic syndrome, postdiarrheal§ 3 128 8 330 292 288 221 200 NE (1), FL (1), CA (1)
Hepatitis C viral, acute 7 1,363 14 878 845 766 652 720 NY (1), MI (1), GA (1), FL (3), TX (1)
HIV infection, pediatric (age <13 years)§§ — — 2 — — — 380 436
Influenza-associated pediatric mortality§,¶¶ 2 115 0 90 77 43 45 — KS (1), TN (1)
Listeriosis 16 470 22 759 808 884 896 753 NY (4), PA (1), OH (1), MI (1), MN (1), MO (1), 
MD (1), VA (1), SC (1), FL (2), AR (1), CA (1)
Measles*** — 55 1 140 43 55 66 37
Meningococcal disease, invasive†††:
 A, C, Y, and W-135 — 185 4 330 325 318 297 —
 serogroup B — 96 2 188 167 193 156 —
 other serogroup 1 19 0 38 35 32 27 — CO (1)
 unknown serogroup 4 324 9 616 550 651 765 — NY (1), MD (1), CA (2)
Mumps 4 263 13 454 800 6,584 314 258 SC (1), FL (2), NV (1)
Novel influenza A virus infections — §§§ 0 2 4 N N N
Plague — 6 0 3 7 17 8 3
Poliomyelitis, paralytic — — — — — — 1 —
Polio virus infection, nonparalytic§ — — — — — N N N
Psittacosis§ — 7 0 8 12 21 16 12
Q fever total §,¶¶¶: 1 57 3 124 171 169 136 70
 acute 1 48 1 110 — — — — MO (1)
 chronic — 9 0 14 — — — —
Rabies, human — 1 0 2 1 3 2 7
Rubella**** — 4 0 16 12 11 11 10
Rubella, congenital syndrome — 1 — — — 1 1 —
SARS-CoV§,†††† — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ — 99 1 157 132 125 129 132
Syphilis, congenital (age <1 yr) — 121 8 434 430 349 329 353
Tetanus 1 7 1 19 28 41 27 34 MO (1)
Toxic-shock syndrome (staphylococcal)§ — 55 2 71 92 101 90 95
Trichinellosis — 12 0 39 5 15 16 5
Tularemia — 47 3 123 137 95 154 134
Typhoid fever 5 244 12 449 434 353 324 322 CT (1), MD (1), FL (2), CA (1)
Vancomycin-intermediate Staphylococcus aureus§ 1 52 1 63 37 6 2 — PA (1)
Vancomycin-resistant Staphylococcus aureus§ — — — — 2 1 3 1
Vibriosis (noncholera Vibrio species infections)§ 13 338 12 492 549 N N N MD (2), VA (1), FL (2), WA (3), CA (5)
Yellow fever — — — — — — — —
See Table I footnotes on next page.
Vol. 58 / No. 36 MMWR 1015
Notifiable Disease Data Team and 122 Cities Mortality Data Team
 Patsy A. Hall
Deborah A. Adams  Rosaline Dhara
Willie J. Anderson  Michael S. Wodajo
Jose Aponte  Pearl C. Sharp
Lenee Blanton
* No measles cases were reported for the current 4-week period yielding a ratio for week 36 of zero (0).
† Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods 
for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of 
these 4-week totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 



























TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — 
United States, week ending September 12, 2009 (36th week)*
—: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts. 
 * Incidence data for reporting year 2008 and 2009 are provisional, whereas data for 2004, 2005, 2006, and 2007 are finalized.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding 
years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and 
influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-
Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, 
human monocytic (analogous to E. chaffeensis); Ehrlichiosis, human granulocytic (analogous to Anaplasma phagocytophilum), and Ehrlichiosis, unspecified, or other agent 
(which included cases unable to be clearly placed in other categories, as well as possible cases of E. ewingii). 
 †† Data for H. influenzae (all ages, all serotypes) are available in Table II.
 §§ Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting 
influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data 
management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 ¶¶ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. A total of 113 influenza-associated pediatric deaths occurring 
during the 2008–09 influenza season have been reported. One influenza-associated pediatric death occurring during the 2009–10 influenza season beginning September 1, 
2009, has been reported.
 *** No measles cases were reported for the current week.
  ††† Data for meningococcal disease (all serogroups) are available in Table II.
 §§§ CDC discontinued reporting of individual confirmed and probable cases of novel influenza A (H1N1) viruses infections on July 24, 2009. CDC will report the total number of 
novel influenza A (H1N1) hospitalizations and deaths weekly on the CDC H1N1 influenza website (http://www.cdc.gov/h1n1flu).
 ¶¶¶ In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not 
differentiated with respect to acute and chronic Q fever cases.
 **** No rubella cases were reported for the current week.
 †††† Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases. 
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52 week Cum  
2009
Cum  
2008Med Max Med Max Med Max
United States 9,302 22,513 25,700 770,096 811,453 175 160 472 7,643 4,444 101 124 401 4,298 5,185
New England 661 766 1,655 27,870 25,465 — 0 1 1 1 3 5 30 238 303
Connecticut 169 222 1,306 7,978 7,349 N 0 0 N N — 0 23 23 41
Maine§ 61 48 75 1,692 1,732 N 0 0 N N — 0 5 22 31
Massachusetts 362 342 945 13,672 12,235 N 0 0 N N 2 2 13 111 126
New Hampshire — 39 63 1,162 1,407 — 0 1 1 1 — 1 4 39 47
Rhode Island§ 69 66 244 2,576 1,939 — 0 0 — — — 0 3 4 7
Vermont§ — 22 53 790 803 N 0 0 N N 1 1 5 39 51
Mid. Atlantic 2,150 2,926 6,734 106,134 100,782 — 0 0 — — 7 13 30 502 507
New Jersey 260 415 838 14,296 15,437 N 0 0 N N — 0 3 8 30
New York (Upstate) 523 580 4,563 21,266 18,506 N 0 0 N N 7 4 13 145 168
New York City 990 1,146 3,130 41,057 38,675 N 0 0 N N — 1 8 50 77
Pennsylvania 377 835 1,072 29,515 28,164 N 0 0 N N — 7 19 299 232
E.N. Central 993 3,494 4,382 116,429 132,748 1 0 4 23 35 10 29 105 947 1,366
Illinois — 1,088 1,367 35,040 40,147 N 0 0 N N — 2 11 93 138
Indiana 279 428 713 16,206 14,903 N 0 0 N N — 3 17 129 128
Michigan 566 853 1,332 31,600 31,276 1 0 3 12 26 3 5 13 172 178
Ohio 41 761 1,300 21,800 31,656 — 0 2 11 9 7 9 59 285 391
Wisconsin 107 346 494 11,783 14,766 N 0 0 N N — 8 40 268 531
W.N. Central 577 1,322 1,664 44,566 45,937 — 0 1 7 1 20 17 47 666 674
Iowa 187 192 256 6,730 6,026 N 0 0 N N — 4 13 154 214
Kansas 9 154 549 5,312 6,296 N 0 0 N N — 1 5 50 55
Minnesota — 254 342 8,070 9,930 — 0 0 — — 11 4 33 194 139
Missouri 318 510 646 18,021 16,818 — 0 1 7 1 2 3 12 122 124
Nebraska§ 63 105 219 3,688 3,657 N 0 0 N N 7 2 5 71 79
North Dakota — 24 60 772 1,250 N 0 0 N N — 0 10 7 2
South Dakota — 58 81 1,973 1,960 N 0 0 N N — 2 6 68 61
S. Atlantic 1,272 4,107 5,453 134,459 165,931 — 0 1 5 3 25 21 49 710 615
Delaware 93 85 180 3,285 2,524 — 0 1 1 1 — 0 1 6 10
District of Columbia 138 126 226 4,737 4,829 — 0 0 — — — 0 2 2 9
Florida 473 1,420 1,597 50,427 49,134 N 0 0 N N 23 8 35 270 270
Georgia 3 753 1,909 20,762 28,834 N 0 0 N N 1 6 23 257 164
Maryland§ 119 426 772 14,450 16,080 — 0 1 4 2 1 1 5 30 28
North Carolina — 0 1,193 — 22,885 N 0 0 N N — 1 16 58 26
South Carolina§ — 534 1,422 16,540 18,073 N 0 0 N N — 1 7 34 36
Virginia§ 446 618 926 21,815 21,370 N 0 0 N N — 1 6 43 53
West Virginia — 68 101 2,443 2,202 N 0 0 N N — 0 2 10 19
E.S. Central 1,160 1,751 2,209 63,042 57,814 — 0 0 — — 2 3 10 132 110
Alabama§ — 475 624 15,693 17,403 N 0 0 N N — 1 4 37 50
Kentucky 134 256 458 9,190 8,099 N 0 0 N N — 1 4 39 23
Mississippi 490 454 841 16,941 13,568 N 0 0 N N — 0 3 10 12
Tennessee§ 536 580 809 21,218 18,744 N 0 0 N N 2 1 5 46 25
W.S. Central 284 2,883 5,300 100,641 102,269 — 0 1 1 3 15 11 271 324 907
Arkansas§ 7 273 418 9,737 9,893 N 0 0 N N — 1 10 32 47
Louisiana 261 420 1,134 14,718 14,642 — 0 1 1 3 — 1 6 29 42
Oklahoma 16 178 2,735 9,589 9,185 N 0 0 N N 5 2 16 85 63
Texas§ — 1,967 2,520 66,597 68,549 N 0 0 N N 10 7 258 178 755
Mountain 451 1,465 2,145 49,220 50,954 126 110 369 5,925 3,011 5 9 22 329 422
Arizona 22 460 735 15,717 16,986 122 108 365 5,853 2,933 — 1 4 25 63
Colorado 189 390 728 12,261 12,022 N 0 0 N N 1 2 10 104 80
Idaho§ 64 68 313 2,437 2,716 N 0 0 N N 3 1 7 57 44
Montana§ — 54 88 1,903 2,109 N 0 0 N N — 0 4 27 38
Nevada§ 126 167 455 6,929 6,732 4 1 3 44 43 — 0 4 14 11
New Mexico§ 50 176 540 5,958 5,290 — 0 2 8 23 1 2 10 74 141
Utah — 99 251 2,679 4,082 — 0 2 20 10 — 0 3 13 30
Wyoming§ — 34 97 1,336 1,017 — 0 1 — 2 — 0 2 15 15
Pacific 1,754 3,645 4,689 127,735 129,553 48 41 172 1,681 1,390 14 11 24 450 281
Alaska — 96 199 3,128 3,225 N 0 0 N N — 0 1 5 3
California 1,213 2,817 3,599 99,468 100,673 48 41 172 1,681 1,390 12 6 20 269 163
Hawaii — 119 247 4,050 3,972 N 0 0 N N — 0 1 1 2
Oregon§ 375 198 631 6,683 6,924 N 0 0 N N 1 3 8 122 51
Washington 166 414 571 14,406 14,759 N 0 0 N N 1 1 6 53 62
American Samoa — 0 0 — 73 N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 2 8 — 107 — 0 0 — — — 0 0 — —
Puerto Rico — 130 332 5,076 5,010 N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 9 17 290 478 — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Chlamydia refers to genital infections caused by Chlamydia trachomatis.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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Haemophilus influenzae, invasive 


















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 235 320 641 11,353 11,945 2,130 5,318 7,164 181,989 229,250 20 60 124 2,147 2,001
New England 12 28 55 943 1,090 96 94 301 3,345 3,586 1 3 16 140 116
Connecticut — 5 14 162 230 48 45 275 1,534 1,682 — 0 12 42 27
Maine§ — 4 12 127 112 6 2 9 96 63 — 0 2 14 9
Massachusetts 10 12 31 429 463 29 39 112 1,374 1,513 1 2 5 71 57
New Hampshire — 2 10 104 110 — 2 6 70 73 — 0 2 7 9
Rhode Island§ — 1 8 35 61 13 6 19 241 228 — 0 7 3 6
Vermont§ 2 3 15 86 114 — 1 4 30 27 — 0 1 3 8
Mid. Atlantic 49 63 116 2,130 2,175 452 592 1,138 21,269 22,425 3 12 25 437 370
New Jersey — 7 17 215 358 66 87 123 2,991 3,695 — 2 7 84 63
New York (Upstate) 36 25 81 851 720 96 109 664 3,950 4,138 — 3 20 103 107
New York City 2 16 30 519 573 197 210 577 7,647 7,059 — 2 11 84 64
Pennsylvania 11 16 46 545 524 93 190 267 6,681 7,533 3 4 10 166 136
E.N. Central 27 44 80 1,492 1,817 307 1,080 1,627 35,965 47,492 6 12 28 472 322
Illinois — 9 23 272 501 — 332 494 10,750 14,000 — 3 9 117 102
Indiana N 0 11 N N 106 149 252 5,257 6,039 — 1 22 50 56
Michigan 7 12 22 406 387 145 281 493 10,174 11,645 — 0 3 16 17
Ohio 20 16 27 553 583 30 245 455 6,793 11,426 3 2 6 76 99
Wisconsin — 8 19 261 346 26 93 140 2,991 4,382 3 3 20 213 48
W.N. Central 20 25 143 1,042 1,304 112 283 393 9,592 11,600 — 3 15 112 148
Iowa 6 6 18 213 208 22 34 53 1,137 1,050 — 0 0 — 2
Kansas — 2 7 70 110 5 36 83 1,360 1,532 — 0 2 11 17
Minnesota — 0 106 250 403 — 43 65 1,328 2,171 — 0 10 40 46
Missouri 10 7 28 332 341 68 129 183 4,539 5,549 — 1 4 37 53
Nebraska§ 4 3 9 118 140 17 23 54 942 994 — 0 4 19 21
North Dakota — 0 16 9 10 — 2 7 43 79 — 0 4 5 9
South Dakota — 1 7 50 92 — 7 20 243 225 — 0 0 — —
S. Atlantic 47 70 109 2,533 1,918 380 1,168 2,042 38,601 58,253 7 13 31 522 510
Delaware — 0 3 18 28 24 16 37 655 770 — 0 1 3 6
District of Columbia — 0 5 16 46 37 51 88 1,870 1,773 — 0 2 — 5
Florida 31 37 59 1,318 795 187 421 486 14,661 16,439 4 4 10 178 132
Georgia 1 13 67 661 475 1 251 876 7,056 10,692 2 3 9 115 104
Maryland§ 7 5 9 170 184 24 121 212 3,845 4,260 1 1 6 65 74
North Carolina N 0 0 N N — 0 470 — 10,072 — 1 17 57 54
South Carolina§ 5 2 8 67 81 — 170 413 5,234 6,588 — 1 5 37 47
Virginia§ 3 8 31 251 257 107 150 308 4,928 7,131 — 1 6 42 70
West Virginia — 1 3 32 52 — 11 23 352 528 — 0 3 25 18
E.S. Central 3 7 20 238 317 364 514 714 18,160 20,939 1 3 9 119 107
Alabama§ — 3 12 111 182 — 142 216 4,432 6,856 — 0 4 26 16
Kentucky N 0 0 N N 37 86 135 2,668 3,172 — 0 5 18 6
Mississippi N 0 0 N N 167 143 252 5,302 4,951 — 0 1 4 11
Tennessee§ 3 4 13 127 135 160 162 273 5,758 5,960 1 2 6 71 74
W.S. Central 8 9 22 306 284 100 865 1,383 29,334 35,156 1 2 22 80 90
Arkansas§ 3 2 8 94 94 1 83 134 3,001 3,230 — 0 2 13 11
Louisiana — 3 8 96 101 83 146 420 4,745 6,345 — 0 1 12 8
Oklahoma 5 4 18 116 89 16 70 613 3,348 3,371 1 1 20 54 64
Texas§ N 0 0 N N — 551 725 18,240 22,210 — 0 1 1 7
Mountain 20 27 59 933 1,060 45 175 313 5,780 8,027 1 5 11 173 226
Arizona — 3 10 135 89 1 54 88 1,785 2,394 — 1 7 60 88
Colorado 14 9 27 342 362 — 56 152 1,697 2,439 1 1 6 54 42
Idaho§ 6 3 10 122 132 3 2 13 70 124 — 0 1 4 12
Montana§ — 2 10 71 61 — 1 6 48 78 — 0 1 1 3
Nevada§ — 2 10 75 78 19 30 91 1,233 1,586 — 0 2 14 14
New Mexico§ — 1 7 66 83 22 24 52 769 960 — 0 3 17 34
Utah — 4 15 91 225 — 4 15 126 357 — 0 2 20 30
Wyoming§ — 1 4 31 30 — 1 7 52 89 — 0 1 3 3
Pacific 49 51 130 1,736 1,980 274 550 765 19,943 21,772 — 2 8 92 112
Alaska — 2 10 67 61 — 15 24 528 361 — 0 3 13 16
California 29 34 57 1,171 1,316 249 468 658 16,766 17,866 — 0 3 22 38
Hawaii — 0 2 9 33 — 12 21 425 432 — 0 3 22 14
Oregon§ 9 7 17 241 318 16 20 48 698 844 — 1 3 32 42
Washington 11 7 74 248 252 9 46 80 1,526 2,269 — 0 2 3 2
American Samoa — 0 0 — — — 0 0 — 3 — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 1 15 — 45 — 0 0 — —
Puerto Rico — 2 15 63 147 — 4 24 166 200 — 0 1 3 1
U.S. Virgin Islands — 0 0 — — — 2 7 80 92 N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 
(36th week)*
Reporting area



















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 17 36 89 1,266 1,856 23 65 197 2,125 2,602 41 51 122 1,903 2,011
New England 1 2 8 65 91 — 1 4 27 58 2 3 18 102 137
Connecticut 1 0 4 17 18 — 0 3 10 23 2 1 5 42 27
Maine§ — 0 5 1 5 — 0 2 8 10 — 0 2 4 6
Massachusetts — 1 3 39 46 — 0 2 6 14 — 1 6 40 58
New Hampshire — 0 1 3 10 — 0 2 3 5 — 0 2 8 24
Rhode Island§ — 0 2 3 10 — 0 0 — 4 — 0 14 4 17
Vermont§ — 0 1 2 2 — 0 1 — 2 — 0 1 4 5
Mid. Atlantic 2 5 13 168 219 — 7 17 219 312 15 15 63 747 663
New Jersey — 1 5 33 55 — 1 6 54 92 — 2 14 119 78
New York (Upstate) 1 1 4 37 44 — 1 11 38 43 11 5 29 245 207
New York City — 2 6 55 74 — 1 4 42 70 — 2 20 133 91
Pennsylvania 1 1 4 43 46 — 3 8 85 107 4 6 25 250 287
E.N. Central — 5 17 175 252 — 8 21 265 356 12 9 29 338 439
Illinois — 1 12 77 92 — 1 6 36 138 — 1 13 26 57
Indiana — 0 3 12 14 — 1 18 46 24 — 1 5 25 38
Michigan — 1 5 47 92 — 2 8 92 98 2 2 10 82 125
Ohio — 1 4 30 29 — 1 13 67 82 10 4 17 200 197
Wisconsin — 0 3 9 25 — 0 4 24 14 — 0 6 5 22
W.N. Central — 2 16 87 205 2 3 16 117 57 — 2 7 65 92
Iowa — 1 2 25 98 — 0 3 23 14 — 0 2 16 13
Kansas — 0 1 7 13 — 0 2 5 6 — 0 1 3 1
Minnesota — 0 12 14 26 — 0 11 20 7 — 0 3 8 9
Missouri — 0 3 20 25 1 1 5 55 24 — 1 5 28 51
Nebraska§ — 0 3 19 39 1 0 2 13 5 — 0 2 8 16
North Dakota — 0 2 — — — 0 1 — 1 — 0 3 1 —
South Dakota — 0 1 2 4 — 0 1 1 — — 0 1 1 2
S. Atlantic 9 7 14 281 274 13 18 32 626 630 8 9 22 323 322
Delaware — 0 1 3 6 U 0 1 U U — 0 5 11 9
District of Columbia U 0 0 U U U 0 0 U U — 0 2 4 12
Florida 5 4 8 132 103 10 6 11 213 220 4 3 7 114 96
Georgia 1 1 3 44 39 3 3 9 101 120 — 1 5 33 26
Maryland§ 2 0 4 28 33 — 1 5 47 57 2 2 10 77 93
North Carolina — 0 4 25 48 — 2 19 130 51 — 0 7 39 16
South Carolina§ — 0 3 27 9 — 1 4 31 51 — 0 1 5 8
Virginia§ 1 0 6 21 31 — 2 10 57 76 — 1 5 34 38
West Virginia — 0 1 1 5 — 0 19 47 55 2 0 1 6 24
E.S. Central — 1 5 30 58 1 7 11 209 269 — 2 11 82 87
Alabama§ — 0 2 7 8 — 2 7 63 76 — 0 1 7 13
Kentucky — 0 2 7 21 — 2 7 53 65 — 1 3 36 41
Mississippi — 0 1 8 4 — 1 2 18 32 — 0 1 3 1
Tennessee§ — 0 2 8 25 1 2 6 75 96 — 1 8 36 32
W.S. Central — 3 43 103 177 3 10 99 332 516 — 1 21 44 58
Arkansas§ — 0 1 4 6 — 1 5 36 42 — 0 2 3 10
Louisiana — 0 1 3 10 — 1 4 33 65 — 0 2 4 8
Oklahoma — 0 6 3 7 2 2 17 71 76 — 0 6 3 3
Texas§ — 3 37 93 154 1 6 76 192 333 — 1 19 34 37
Mountain 1 3 7 113 166 1 3 7 93 144 2 2 8 75 58
Arizona — 2 6 54 84 — 1 4 36 56 1 1 4 35 14
Colorado — 0 5 34 29 — 0 2 16 24 — 0 2 7 6
Idaho§ — 0 1 3 16 — 0 2 6 7 — 0 1 1 3
Montana§ — 0 1 5 1 — 0 0 — 2 — 0 2 4 4
Nevada§ 1 0 3 7 7 1 0 3 22 30 1 0 2 10 8
New Mexico§ — 0 1 6 15 — 0 2 5 8 — 0 2 2 5
Utah — 0 1 4 11 — 0 1 5 12 — 0 4 15 18
Wyoming§ — 0 0 — 3 — 0 2 3 5 — 0 1 1 —
Pacific 4 7 17 244 414 3 6 36 237 260 2 3 12 127 155
Alaska — 0 1 3 3 — 0 1 2 9 — 0 1 1 1
California 4 5 17 193 335 3 5 28 174 178 2 3 9 102 119
Hawaii — 0 1 5 15 — 0 1 4 6 — 0 1 1 6
Oregon§ — 0 2 12 23 — 0 4 26 32 — 0 2 8 14
Washington — 1 4 31 38 — 1 8 31 35 — 0 4 15 15
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 2 17 20 — 0 3 12 41 — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Data for acute hepatitis C, viral are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 187 500 1,637 19,400 23,797 6 23 46 768 812 5 17 48 624 872
New England 2 103 327 3,347 8,936 — 1 5 30 43 — 0 4 21 23
Connecticut — 0 105 — 3,086 — 0 4 5 10 — 0 1 2 1
Maine§ — 9 73 467 312 — 0 1 1 1 — 0 1 3 4
Massachusetts 2 30 213 1,881 3,827 — 0 3 19 23 — 0 3 12 15
New Hampshire — 13 73 750 1,299 — 0 1 2 3 — 0 1 1 2
Rhode Island§ — 0 78 54 119 — 0 1 1 2 — 0 1 2 1
Vermont§ — 4 35 195 293 — 0 1 2 4 — 0 1 1 —
Mid. Atlantic 115 247 1,401 11,621 9,529 — 5 17 175 219 1 2 5 71 96
New Jersey — 35 264 2,629 2,837 — 0 3 — 54 — 0 2 8 13
New York (Upstate) 77 87 1,368 2,965 3,117 — 1 10 36 22 1 0 2 18 25
New York City — 3 33 92 584 — 3 11 103 116 — 0 2 12 19
Pennsylvania 38 53 608 5,935 2,991 — 1 4 36 27 — 1 4 33 39
E.N. Central 4 19 179 1,549 1,893 2 3 8 105 114 — 3 8 100 151
Illinois — 1 10 80 97 — 1 4 46 61 — 1 6 26 54
Indiana — 1 4 33 31 — 0 1 7 5 — 0 3 24 22
Michigan — 1 10 76 61 — 0 3 17 13 — 0 5 18 25
Ohio 1 1 3 33 33 2 1 6 31 22 — 0 3 26 32
Wisconsin 3 15 165 1,327 1,671 — 0 2 4 13 — 0 1 6 18
W.N. Central 1 5 336 171 441 — 1 7 39 46 — 1 9 49 76
Iowa — 1 12 71 90 — 0 3 8 5 — 0 1 6 15
Kansas — 0 4 15 6 — 0 2 3 4 — 0 2 7 4
Minnesota — 0 326 67 330 — 0 7 13 19 — 0 4 10 21
Missouri — 0 2 4 4 — 0 2 9 10 — 0 3 18 23
Nebraska§ 1 0 3 13 8 — 0 1 5 8 — 0 1 5 10
North Dakota — 0 10 — — — 0 0 — — — 0 3 1 1
South Dakota — 0 1 1 3 — 0 1 1 — — 0 1 2 2
S. Atlantic 59 63 207 2,476 2,767 1 6 17 237 204 1 2 9 114 122
Delaware 2 12 63 727 605 — 0 1 3 2 — 0 1 2 1
District of Columbia — 0 5 18 54 — 0 2 5 2 — 0 0 — —
Florida 8 1 9 55 45 — 2 7 69 36 — 1 4 42 42
Georgia — 0 6 39 31 — 1 5 51 46 — 0 2 21 14
Maryland§ 18 29 130 1,140 1,374 1 1 8 52 53 1 0 1 7 13
North Carolina — 1 14 56 15 — 0 5 21 22 — 0 5 18 11
South Carolina§ — 0 3 19 18 — 0 1 2 8 — 0 1 10 19
Virginia§ 4 12 61 322 518 — 1 4 32 33 — 0 2 9 17
West Virginia 27 0 17 100 107 — 0 1 2 2 — 0 2 5 5
E.S. Central 1 0 2 19 39 1 0 3 24 13 — 0 3 21 39
Alabama§ — 0 1 2 9 — 0 3 6 3 — 0 1 5 5
Kentucky — 0 1 1 4 — 0 2 8 4 — 0 1 4 7
Mississippi — 0 0 — 1 — 0 1 1 1 — 0 1 2 9
Tennessee§ 1 0 2 16 25 1 0 3 9 5 — 0 1 10 18
W.S. Central — 1 21 37 71 — 1 8 34 52 — 1 12 58 94
Arkansas§ — 0 0 — — — 0 1 3 — — 0 2 5 13
Louisiana — 0 0 — 3 — 0 1 3 2 — 0 3 11 19
Oklahoma — 0 2 — — — 0 2 2 2 — 0 3 6 12
Texas§ — 1 21 37 68 — 1 7 26 48 — 1 9 36 50
Mountain 1 1 13 32 42 — 0 4 22 21 1 1 4 50 46
Arizona — 0 2 3 7 — 0 2 6 10 — 0 2 13 6
Colorado 1 0 1 4 3 — 0 3 8 3 1 0 2 16 9
Idaho§ — 0 2 9 6 — 0 1 1 — — 0 1 5 4
Montana§ — 0 13 2 4 — 0 3 4 — — 0 2 4 4
Nevada§ — 0 2 12 10 — 0 1 — 4 — 0 2 4 7
New Mexico§ — 0 1 1 8 — 0 1 — 2 — 0 1 3 7
Utah — 0 1 — 2 — 0 2 3 2 — 0 1 1 7
Wyoming§ — 0 1 1 2 — 0 0 — — — 0 2 4 2
Pacific 4 4 13 148 79 2 3 10 102 100 2 3 14 140 225
Alaska — 0 1 2 5 — 0 1 2 4 — 0 2 4 6
California 2 3 12 127 41 2 2 8 77 72 2 2 8 94 166
Hawaii N 0 0 N N — 0 1 1 2 — 0 1 3 4
Oregon§ — 0 3 12 26 — 0 2 9 4 — 0 6 26 26
Washington 2 0 12 7 7 — 0 3 13 18 — 0 6 13 23
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 2 — 1 — 0 0 — —
Puerto Rico N 0 0 N N — 0 1 2 2 — 0 1 — 2
U.S. Virgin Islands N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 
(36th week)*
Reporting area
























2008Med Max Med Max Med Max
United States 97 273 1,697 8,953 6,262 32 69 138 2,514 3,013 6 32 179 1,029 1,654
New England 3 14 27 428 712 1 8 14 225 282 — 0 2 9 4
Connecticut — 0 4 26 40 — 3 10 101 138 — 0 0 — —
Maine† — 1 10 64 25 — 1 5 36 36 — 0 2 4 1
Massachusetts 3 8 21 266 557 — 0 0 — — — 0 1 4 1
New Hampshire — 1 7 53 22 — 0 7 24 29 — 0 0 — 1
Rhode Island† — 0 5 11 59 — 0 3 27 25 — 0 2 — 1
Vermont† — 0 2 8 9 1 1 4 37 54 — 0 1 1 —
Mid. Atlantic 11 22 64 769 733 10 14 27 439 653 1 1 29 52 105
New Jersey — 4 12 128 155 — 0 0 — — — 0 2 — 72
New York (Upstate) 9 5 41 145 278 10 8 20 320 357 — 0 29 10 12
New York City — 0 21 53 49 — 0 2 1 13 — 0 4 23 10
Pennsylvania 2 13 33 443 251 — 5 17 118 283 1 0 2 19 11
E.N. Central 25 54 238 1,841 1,029 4 2 19 185 195 — 1 6 60 124
Illinois — 11 45 284 206 3 1 9 77 81 — 1 6 37 91
Indiana — 4 158 179 40 — 0 6 17 6 — 0 3 4 6
Michigan 7 11 27 480 167 — 1 5 50 64 — 0 2 5 3
Ohio 18 20 57 792 517 1 0 7 41 44 — 0 4 14 24
Wisconsin — 3 12 106 99 N 0 0 N N — 0 0 — —
W.N. Central 8 34 872 1,262 522 8 5 17 206 213 2 4 25 223 360
Iowa — 6 21 135 82 — 0 5 24 17 — 0 2 4 7
Kansas — 4 12 132 42 — 1 6 56 50 — 0 1 2 —
Minnesota — 0 808 165 156 4 0 11 44 34 — 0 1 2 —
Missouri 6 20 51 688 165 4 1 5 51 49 2 4 24 204 334
Nebraska† 2 4 32 110 54 — 0 2 — 29 — 0 2 11 16
North Dakota — 0 24 17 1 — 0 9 4 17 — 0 1 — —
South Dakota — 0 10 15 22 — 0 4 27 17 — 0 0 — 3
S. Atlantic 27 28 71 1,133 615 8 25 111 1,109 1,253 — 13 42 376 560
Delaware — 0 2 10 11 — 0 0 — — — 0 3 15 26
District of Columbia — 0 2 2 3 — 0 0 — — — 0 0 — 6
Florida 18 8 32 410 189 — 0 95 123 138 — 0 2 5 9
Georgia — 3 11 106 62 — 0 71 262 279 — 1 6 37 66
Maryland† — 3 9 78 84 7 6 14 264 323 — 1 3 27 69
North Carolina — 0 65 204 79 N 2 4 N N — 7 36 225 245
South Carolina† 1 4 17 171 85 — 0 0 — — — 0 9 16 30
Virginia† 8 3 24 128 95 — 10 23 375 446 — 2 9 47 101
West Virginia — 0 5 24 7 1 2 6 85 67 — 0 1 4 8
E.S. Central 4 15 33 568 220 — 2 7 70 135 2 4 19 182 241
Alabama† — 4 19 216 30 — 0 0 — — — 1 6 39 63
Kentucky — 6 15 178 59 — 1 4 36 33 — 0 1 1 1
Mississippi — 1 4 41 77 — 0 2 — 2 — 0 1 7 10
Tennessee† 4 3 14 133 54 — 1 4 34 100 2 3 15 135 167
W.S. Central 4 55 389 1,779 995 — 0 13 45 75 1 1 161 106 224
Arkansas† 3 4 38 171 64 — 0 5 23 41 — 0 61 47 44
Louisiana — 2 8 90 63 — 0 0 — — — 0 1 2 5
Oklahoma 1 0 45 37 32 — 0 13 21 32 — 0 98 44 142
Texas† — 41 304 1,481 836 — 0 1 1 2 1 0 6 13 33
Mountain 8 17 31 594 602 — 1 9 57 67 — 1 3 19 33
Arizona — 4 10 152 166 N 0 0 N N — 0 2 4 8
Colorado 3 5 12 200 111 — 0 0 — — — 0 0 — 1
Idaho† 5 1 5 60 22 — 0 2 — 8 — 0 1 1 1
Montana† — 0 4 12 75 — 0 4 16 7 — 0 2 8 3
Nevada† — 0 3 10 26 — 0 1 4 10 — 0 1 1 2
New Mexico† — 1 10 39 32 — 0 2 16 23 — 0 1 1 4
Utah — 3 19 113 159 — 0 6 4 7 — 0 1 1 5
Wyoming† — 0 5 8 11 — 0 4 17 12 — 0 1 3 9
Pacific 7 19 98 579 834 1 5 12 178 140 — 0 1 2 3
Alaska — 1 21 31 110 — 0 2 10 12 N 0 0 N N
California — 5 19 143 378 1 4 12 153 121 — 0 1 2 —
Hawaii — 0 3 22 10 — 0 0 — — N 0 0 N N
Oregon† — 3 16 183 125 — 0 3 15 7 — 0 0 — 3
Washington 7 6 76 200 211 — 0 0 — — — 0 0 — —
American Samoa — 0 0 — — N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — N 0 0 N N
Puerto Rico — 0 1 1 — — 1 3 27 46 N 0 0 N N
U.S. Virgin Islands — 0 0 — — N 0 0 N N N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 
(36th week)*
Reporting area


















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 648 916 2,323 28,712 31,353 54 86 255 2,644 3,309 146 314 1,268 10,290 13,352
New England 3 32 324 1,511 1,691 — 3 50 156 179 — 3 33 234 176
Connecticut — 0 298 298 491 — 0 50 50 47 — 0 28 28 40
Maine§ — 2 7 83 104 — 0 3 14 13 — 0 1 2 18
Massachusetts 3 23 39 805 848 — 1 6 58 85 — 3 27 183 101
New Hampshire — 3 42 198 107 — 1 3 23 14 — 0 3 8 4
Rhode Island§ — 2 11 87 73 — 0 1 — 7 — 0 1 8 10
Vermont§ — 1 5 40 68 — 0 6 11 13 — 0 2 5 3
Mid. Atlantic 45 91 182 3,102 3,956 5 7 18 237 341 10 56 79 1,955 1,690
New Jersey — 10 41 237 941 — 1 5 31 103 — 13 35 416 571
New York (Upstate) 27 24 66 897 901 4 3 9 96 111 4 5 23 160 446
New York City 2 19 49 776 886 — 1 5 39 36 1 9 23 294 539
Pennsylvania 16 29 66 1,192 1,228 1 1 5 71 91 5 24 61 1,085 134
E.N. Central 33 91 141 3,243 3,589 2 12 74 428 531 5 64 132 1,856 2,592
Illinois — 25 50 845 1,054 — 1 10 65 89 — 13 25 367 727
Indiana — 7 50 245 415 — 1 6 39 68 — 1 21 38 499
Michigan 2 18 29 666 672 1 3 43 101 94 1 5 24 162 91
Ohio 30 27 52 1,057 906 1 3 15 101 121 2 36 80 933 996
Wisconsin 1 12 30 430 542 — 3 10 122 159 2 11 42 356 279
W.N. Central 30 50 109 1,878 2,009 10 12 38 508 579 17 15 49 622 658
Iowa 2 7 15 301 315 1 2 14 122 150 — 2 12 47 117
Kansas — 6 19 225 327 — 1 7 30 31 — 3 11 147 28
Minnesota 13 13 51 452 513 6 2 17 152 117 7 2 14 65 227
Missouri 12 12 31 434 545 2 2 10 83 122 10 4 40 338 174
Nebraska§ 3 5 41 272 171 1 2 6 66 120 — 0 3 19 5
North Dakota — 0 30 40 31 — 0 28 3 1 — 0 9 3 32
South Dakota — 3 22 154 107 — 0 12 52 38 — 0 1 3 75
S. Atlantic 255 262 440 7,798 7,622 10 13 30 433 588 18 47 85 1,593 2,225
Delaware 1 2 8 72 110 — 0 2 11 10 3 1 8 75 7
District of Columbia — 0 5 20 49 — 0 1 1 5 — 0 2 6 16
Florida 170 115 197 3,683 3,098 3 3 7 115 100 9 8 24 313 622
Georgia 36 39 96 1,462 1,493 1 1 4 50 68 3 13 30 458 815
Maryland§ 16 15 26 502 592 3 1 8 60 95 2 6 14 257 69
North Carolina — 23 104 778 755 — 2 21 74 65 — 6 27 251 112
South Carolina§ 20 15 54 496 703 — 0 3 21 32 1 3 14 86 431
Virginia§ 11 21 88 626 671 2 2 16 82 181 — 5 59 141 125
West Virginia 1 4 23 159 151 1 0 3 19 32 — 0 3 6 28
E.S. Central 11 56 140 1,838 2,242 2 4 12 147 195 2 19 58 575 1,364
Alabama§ — 15 40 436 639 — 1 4 33 49 — 4 11 97 325
Kentucky — 10 18 335 308 — 2 7 52 63 — 2 25 143 209
Mississippi 1 14 57 551 749 — 0 1 6 4 — 1 4 29 273
Tennessee§ 10 15 62 516 546 2 2 5 56 79 2 11 48 306 557
W.S. Central 119 110 1,333 3,086 4,325 4 4 139 103 237 44 56 967 1,814 2,940
Arkansas§ 9 12 34 411 508 1 0 5 26 37 2 8 20 236 388
Louisiana — 16 43 599 754 — 0 1 — 7 — 4 17 108 498
Oklahoma 18 14 102 440 508 2 1 82 21 22 11 5 61 197 93
Texas§ 92 56 1,204 1,636 2,555 1 2 55 56 171 31 42 889 1,273 1,961
Mountain 29 57 113 1,980 2,322 1 10 40 319 387 17 25 54 816 658
Arizona 12 20 48 705 727 1 1 4 55 50 13 17 41 611 320
Colorado 14 13 34 471 515 — 3 18 104 106 3 2 11 67 75
Idaho§ 2 4 10 131 120 — 2 15 58 79 — 0 2 7 9
Montana§ — 2 7 73 86 — 0 3 15 28 — 0 5 13 5
Nevada§ 1 4 13 180 162 — 0 4 20 13 1 1 11 48 153
New Mexico§ — 5 25 214 416 — 1 2 21 41 — 2 12 59 67
Utah — 6 15 163 244 — 1 5 41 60 — 0 3 11 26
Wyoming§ — 1 6 43 52 — 0 2 5 10 — 0 1 — 3
Pacific 123 126 537 4,276 3,597 20 10 31 313 272 33 27 82 825 1,049
Alaska — 1 6 56 41 — 0 1 — 5 — 0 1 2 —
California 97 95 516 3,248 2,595 7 5 15 165 123 26 20 75 665 906
Hawaii 4 5 13 177 189 — 0 1 3 11 1 0 4 27 33
Oregon§ 2 8 15 282 319 3 1 6 47 48 1 1 10 28 52
Washington 20 12 85 513 453 10 3 16 98 85 5 2 11 103 58
American Samoa — 0 1 — 2 — 0 0 — — — 0 2 3 1
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 — 10 — 0 0 — — — 0 1 — 14
Puerto Rico 2 8 40 249 484 — 0 1 1 — — 0 2 7 22
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 
(36th week)*
Reporting area
Streptococcal diseases, invasive, group A












52 weeks Cum  
2009
Cum  
2008Med Max Med Max
United States 27 101 239 3,875 4,142 14 36 122 1,191 1,238
New England — 5 28 229 299 — 1 12 43 60
Connecticut — 0 21 63 86 — 0 11 — —
Maine§ — 0 2 13 20 — 0 1 3 1
Massachusetts — 3 10 97 140 — 1 4 30 44
New Hampshire — 1 4 34 20 — 0 2 8 8
Rhode Island§ — 0 2 9 21 — 0 2 — 7
Vermont§  — 0 3 13 12 — 0 1 2 —
Mid. Atlantic 3 19 43 784 850 1 5 33 181 155
New Jersey — 3 6 104 154 — 1 4 31 47
New York (Upstate) 3 7 25 261 265 — 2 17 85 69
New York City — 4 12 149 154 1 0 31 65 39
Pennsylvania — 6 18 270 277 N 0 2 N N
E.N. Central 1 17 42 735 787 1 6 18 180 226
Illinois — 5 12 204 210 — 1 5 23 63
Indiana — 3 23 117 104 — 0 13 26 26
Michigan — 3 11 120 136 — 1 5 48 58
Ohio — 4 13 185 215 1 1 6 53 42
Wisconsin 1 2 11 109 122 — 1 4 30 37
W.N. Central — 6 37 319 313 — 2 11 107 68
Iowa — 0 0 — — — 0 0 — —
Kansas — 1 5 37 32 N 0 1 N N
Minnesota — 0 34 146 150 — 0 10 60 19
Missouri — 1 8 70 74 — 0 4 29 30
Nebraska§ — 1 3 35 31 — 0 1 8 7
North Dakota — 0 4 11 8 — 0 3 4 6
South Dakota — 0 3 20 18 — 0 2 6 6
S. Atlantic 9 22 48 884 843 5 6 16 221 242
Delaware 1 0 1 10 6 — 0 0 — —
District of Columbia — 0 3 11 12 N 0 0 N N
Florida 5 6 12 217 193 3 1 6 52 46
Georgia 1 5 13 208 187 1 2 6 55 65
Maryland§ 2 3 12 140 146 — 1 4 51 46
North Carolina — 2 12 81 106 N 0 0 N N
South Carolina§ — 1 5 56 51 1 1 6 33 42
Virginia§ — 3 9 127 109 — 0 4 18 37
West Virginia — 1 4 34 33 — 0 3 12 6
E.S. Central 1 4 10 148 145 3 2 7 64 63
Alabama§ N 0 0 N N N 0 0 N N
Kentucky — 1 5 28 31 N 0 0 N N
Mississippi N 0 0 N N — 0 2 14 8
Tennessee§ 1 3 9 120 114 3 1 6 50 55
W.S. Central 4 9 79 324 366 4 6 46 203 192
Arkansas§ — 0 2 14 8 — 0 4 21 11
Louisiana — 0 3 11 14 — 0 3 13 11
Oklahoma — 3 20 108 85 3 1 7 43 49
Texas§ 4 5 59 191 259 1 4 34 126 121
Mountain 6 10 22 338 429 — 4 16 169 194
Arizona 3 3 7 115 151 — 2 10 88 89
Colorado 3 3 9 111 107 — 1 4 32 43
Idaho§ — 0 2 7 12 — 0 2 7 3
Montana§ N 0 0 N N N 0 0 N N
Nevada§ — 0 1 5 8 — 0 1 — 3
New Mexico§ — 2 7 59 103 — 0 4 15 27
Utah — 1 6 40 42 — 0 5 27 28
Wyoming§ — 0 1 1 6 — 0 1 — 1
Pacific 3 3 9 114 110 — 0 4 23 38
Alaska — 1 3 21 28 — 0 3 17 24
California N 0 0 N N N 0 0 N N
Hawaii 3 3 8 93 82 — 0 2 6 14
Oregon§ N 0 0 N N N 0 0 N N
Washington N 0 0 N N N 0 0 N N
American Samoa — 0 0 — 30 N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 0 0 — — — 0 0 — —
Puerto Rico N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 0 0 — — N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by S. pneumoniae, which is susceptible or for which susceptibility testing is not available 
(NNDSS event code 11717).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 
(36th week)*
Reporting area
Streptococcus pneumoniae, invasive disease, drug resistant†


















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 11 60 276 2,007 2,230 3 9 21 312 341 80 262 452 8,929 8,767
New England — 1 48 35 46 — 0 5 3 7 3 5 15 228 218
Connecticut — 0 48 — — — 0 5 — — 1 1 5 42 21
Maine§ — 0 2 9 15 — 0 1 1 1 — 0 1 1 9
Massachusetts — 0 1 3 — — 0 1 2 — 2 4 11 161 155
New Hampshire — 0 3 5 — — 0 0 — — — 0 2 12 13
Rhode Island§ — 0 6 7 18 — 0 1 — 4 — 0 5 12 14
Vermont§ — 0 2 11 13 — 0 0 — 2 — 0 2 — 6
Mid. Atlantic — 3 14 117 230 — 0 3 20 20 21 35 51 1,278 1,155
New Jersey — 0 0 — — — 0 0 — — 2 4 13 157 152
New York (Upstate) — 1 10 52 48 — 0 2 10 6 1 2 8 86 93
New York City — 0 4 3 93 — 0 2 — 1 16 23 40 802 721
Pennsylvania — 1 8 62 89 — 0 2 10 13 2 6 12 233 189
E.N. Central 1 11 41 450 476 — 1 7 64 64 15 23 44 730 800
Illinois N 0 0 N N N 0 0 N N — 7 19 203 322
Indiana — 3 32 161 163 — 0 6 22 20 5 2 10 115 98
Michigan — 0 2 19 17 — 0 1 2 2 10 3 18 175 129
Ohio 1 7 18 270 296 — 1 4 40 42 — 6 17 206 212
Wisconsin — 0 0 — — — 0 0 — — — 1 4 31 39
W.N. Central — 2 161 94 157 — 0 3 20 32 3 6 11 214 294
Iowa — 0 0 — — — 0 0 — — 1 0 2 17 14
Kansas — 1 5 39 59 — 0 2 13 4 2 0 3 22 24
Minnesota — 0 156 — 23 — 0 3 — 23 — 1 6 40 73
Missouri — 1 5 43 67 — 0 1 5 2 — 3 7 117 173
Nebraska§ — 0 0 — — — 0 0 — — — 0 3 14 10
North Dakota — 0 3 10 2 — 0 0 — — — 0 1 3 —
South Dakota — 0 2 2 6 — 0 2 2 3 — 0 1 1 —
S. Atlantic 10 26 53 956 913 3 4 14 143 149 24 64 262 2,227 1,931
Delaware — 0 2 15 3 — 0 0 — — 1 0 3 23 10
District of Columbia N 0 0 N N N 0 0 N N 3 3 9 120 94
Florida 9 15 36 559 521 3 2 13 89 97 — 20 31 672 717
Georgia 1 8 25 291 303 — 1 5 47 44 3 14 227 522 437
Maryland§ — 0 1 4 4 — 0 0 — 1 5 6 16 216 236
North Carolina N 0 0 N N N 0 0 N N 4 9 21 365 188
South Carolina§ — 0 0 — — — 0 0 — — — 2 6 81 58
Virginia§ N 0 0 N N N 0 0 N N 8 6 15 224 183
West Virginia — 2 13 87 82 — 0 3 7 7 — 0 2 4 8
E.S. Central — 5 25 196 237 — 1 3 29 43 11 22 36 785 746
Alabama§ N 0 0 N N N 0 0 N N — 8 17 288 310
Kentucky — 1 5 55 58 — 0 2 7 9 1 1 10 47 60
Mississippi — 0 3 3 28 — 0 1 2 8 6 4 18 158 103
Tennessee§ — 3 23 138 151 — 0 3 20 26 4 8 19 292 273
W.S. Central — 1 6 72 76 — 0 3 14 12 — 49 80 1,641 1,480
Arkansas§ — 1 5 40 13 — 0 3 9 3 — 4 35 151 112
Louisiana — 1 5 32 63 — 0 1 5 9 — 11 40 303 403
Oklahoma N 0 0 N N N 0 0 N N — 1 7 43 53
Texas§ — 0 0 — — — 0 0 — — — 32 48 1,144 912
Mountain — 2 7 84 93 — 0 3 17 12 1 9 18 298 443
Arizona — 0 0 — — — 0 0 — — — 4 9 132 226
Colorado — 0 0 — — — 0 0 — — — 1 4 61 108
Idaho§ N 0 1 N N N 0 1 N N — 0 2 3 2
Montana§ — 0 1 — — — 0 0 — — — 0 7 — —
Nevada§ — 1 4 33 44 — 0 2 7 5 1 1 7 66 58
New Mexico§ — 0 0 — — — 0 0 — — — 1 5 34 30
Utah — 1 6 42 48 — 0 3 9 7 — 0 2 — 16
Wyoming§ — 0 2 9 1 — 0 1 1 — — 0 1 2 3
Pacific — 0 1 3 2 — 0 1 2 2 2 44 66 1,528 1,700
Alaska — 0 0 — — — 0 0 — — — 0 0 — 1
California N 0 0 N N N 0 0 N N 1 39 59 1,392 1,536
Hawaii — 0 1 3 2 — 0 1 2 2 — 0 3 20 16
Oregon§ N 0 0 N N N 0 0 N N — 1 4 32 13
Washington N 0 0 N N N 0 0 N N 1 2 7 84 134
American Samoa N 0 0 N N N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 3 16 142 101
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Includes cases of invasive pneumococcal disease caused by drug-resistant S. pneumoniae (DRSP) (NNDSS event code 11720).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
1024 MMWR September 18, 2009
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 
(36th week)*
West Nile virus disease†
Reporting area


















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 74 451 1,035 12,328 20,816 1 1 70 137 480 — 1 37 142 538
New England — 8 46 195 1,161 — 0 2 — 3 — 0 0 — 3
Connecticut — 0 21 — 600 — 0 2 — 3 — 0 0 — 3
Maine¶ — 0 11 5 177 — 0 0 — — — 0 0 — —
Massachusetts — 0 2 2 — — 0 1 — — — 0 0 — —
New Hampshire — 4 11 141 186 — 0 0 — — — 0 0 — —
Rhode Island¶ — 0 1 4 — — 0 1 — — — 0 0 — —
Vermont¶ — 2 17 43 198 — 0 0 — — — 0 0 — —
Mid. Atlantic 10 39 58 1,065 1,658 — 0 6 2 31 — 0 2 — 15
New Jersey N 0 0 N N — 0 2 — 2 — 0 0 — 4
New York (Upstate) N 0 0 N N — 0 3 1 15 — 0 2 — 4
New York City — 0 0 — — — 0 2 — 6 — 0 1 — 5
Pennsylvania 10 39 58 1,065 1,658 — 0 1 1 8 — 0 0 — 2
E.N. Central 20 155 254 4,282 5,038 — 0 7 2 23 — 0 2 1 15
Illinois — 35 73 904 742 — 0 4 1 4 — 0 1 — 7
Indiana — 2 19 211 — — 0 1 1 2 — 0 1 — —
Michigan 5 48 90 1,322 2,105 — 0 2 — 7 — 0 1 — 4
Ohio 13 42 91 1,455 1,611 — 0 3 — 8 — 0 1 1 —
Wisconsin 2 13 55 390 580 — 0 2 — 2 — 0 0 — 4
W.N. Central 7 22 114 682 823 — 0 6 8 35 — 0 4 27 114
Iowa N 0 0 N N — 0 1 — 2 — 0 1 2 2
Kansas — 5 22 176 323 — 0 2 — 9 — 0 2 4 12
Minnesota — 0 0 — — — 0 0 — 2 — 0 1 1 8
Missouri 7 10 51 449 465 — 0 3 1 5 — 0 1 — 2
Nebraska¶ N 0 0 N N — 0 2 4 4 — 0 3 10 29
North Dakota — 0 108 57 — — 0 0 — 2 — 0 1 1 35
South Dakota — 0 4 — 35 — 0 2 3 11 — 0 2 9 26
S. Atlantic 17 57 146 1,450 3,398 — 0 2 3 15 — 0 3 — 15
Delaware — 0 4 8 30 — 0 0 — — — 0 0 — 1
District of Columbia — 0 3 8 18 — 0 0 — 4 — 0 1 — 2
Florida 11 28 67 938 1,195 — 0 0 — 3 — 0 0 — —
Georgia N 0 0 N N — 0 1 2 2 — 0 0 — 4
Maryland¶ N 0 0 N N — 0 2 — 3 — 0 2 — 5
North Carolina N 0 0 N N — 0 0 — 2 — 0 0 — 1
South Carolina¶ — 3 54 154 602 — 0 1 1 — — 0 0 — 1
Virginia¶ — 0 119 28 1,034 — 0 0 — — — 0 0 — 1
West Virginia 6 9 32 314 519 — 0 0 — 1 — 0 0 — —
E.S. Central — 11 28 358 879 — 0 5 23 37 — 0 5 13 50
Alabama¶ — 11 28 356 869 — 0 1 — 10 — 0 2 — 5
Kentucky N 0 0 N N — 0 1 1 — — 0 0 — —
Mississippi — 0 1 2 10 — 0 5 21 18 — 0 3 12 38
Tennessee¶ N 0 0 N N — 0 2 1 9 — 0 1 1 7
W.S. Central — 94 747 3,259 6,243 — 0 8 41 55 — 0 5 16 45
Arkansas¶ — 3 47 96 495 — 0 1 1 6 — 0 0 — 2
Louisiana — 1 7 76 57 — 0 3 6 13 — 0 5 6 18
Oklahoma N 0 0 N N — 0 1 4 2 — 0 0 — 5
Texas¶ — 86 721 3,087 5,691 — 0 7 30 34 — 0 3 10 20
Mountain 20 33 83 957 1,524 — 0 8 39 68 — 0 15 60 148
Arizona — 0 0 — — — 0 5 11 37 — 0 8 4 27
Colorado 20 12 44 388 622 — 0 4 13 13 — 0 11 38 51
Idaho¶ N 0 0 N N — 0 1 2 3 — 0 2 6 32
Montana¶ — 2 20 105 230 — 0 1 2 — — 0 1 1 5
Nevada¶ N 0 0 N N — 0 2 7 7 — 0 1 5 6
New Mexico¶ — 2 20 134 166 — 0 1 2 4 — 0 1 1 1
Utah — 13 31 330 496 — 0 1 — 4 — 0 1 — 18
Wyoming¶ — 0 1 — 10 — 0 1 2 — — 0 2 5 8
Pacific — 2 7 80 92 1 0 34 19 213 — 0 10 25 133
Alaska — 1 6 50 44 — 0 0 — — — 0 0 — —
California — 0 0 — — 1 0 33 16 209 — 0 10 18 119
Hawaii — 1 4 30 48 — 0 0 — — — 0 0 — —
Oregon¶ N 0 0 N N — 0 1 — 2 — 0 0 — 13
Washington N 0 0 N N — 0 2 3 2 — 0 3 7 1
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 2 3 — 55 — 0 0 — — — 0 0 — —
Puerto Rico — 8 23 318 442 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not reportable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). 
Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and 
influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE III. Deaths in 122 U.S. cities,* week ending September 12, 2009 (36th week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages ≥65 45–64 25–44 1–24 <1
All  
Ages ≥65 45–64 25–44 1–24 <1
New England 458 304 94 33 15 12 44 S. Atlantic 1,077 656 295 72 25 29 38
Boston, MA 118 68 29 10 6 5 6 Atlanta, GA 109 67 25 9 3 5 4
Bridgeport, CT 15 12 3 — — — — Baltimore, MD 145 86 43 11 2 3 12
Cambridge, MA 13 11 1 1 — — 1 Charlotte, NC 86 53 26 4 3 — 1
Fall River, MA 14 9 2 2 1 — 2 Jacksonville, FL 150 87 49 8 3 3 1
Hartford, CT 30 18 8 2 1 1 1 Miami, FL 82 53 18 5 3 3 2
Lowell, MA 31 25 3 3 — — 1 Norfolk, VA 29 18 8 3 — — 2
Lynn, MA 10 10 — — — — — Richmond, VA 43 23 15 2 2 1 —
New Bedford, MA 27 19 4 4 — — 3 Savannah, GA 38 20 10 2 — 6 1
New Haven, CT 22 15 7 — — — 4 St. Petersburg, FL 48 34 9 3 2 — 3
Providence, RI 62 37 14 6 5 — 8 Tampa, FL 159 107 36 9 3 4 7
Somerville, MA 1 — 1 — — — — Washington, D.C. 183 105 54 16 4 4 5
Springfield, MA 30 18 7 2 1 2 6 Wilmington, DE 5 3 2 — — — —
Waterbury, CT 15 13 1 1 — — 2 E.S. Central 756 486 183 44 28 15 54
Worcester, MA 70 49 14 2 1 4 10 Birmingham, AL 173 115 34 8 8 8 10
Mid. Atlantic 1,678 1,156 363 94 38 27 73 Chattanooga, TN 52 38 9 1 3 1 4
Albany, NY 50 36 6 3 1 4 2 Knoxville, TN 95 61 24 3 7 — 6
Allentown, PA 23 20 2 — 1 — — Lexington, KY 62 44 10 6 1 1 4
Buffalo, NY 81 59 16 3 3 — 3 Memphis, TN 139 83 39 10 6 1 10
Camden, NJ 39 20 11 2 1 5 — Mobile, AL 60 38 19 1 1 1 —
Elizabeth, NJ 10 6 2 2 — — — Montgomery, AL 58 35 17 5 1 — 5
Erie, PA 49 31 13 1 2 2 4 Nashville, TN 117 72 31 10 1 3 15
Jersey City, NJ 32 19 9 2 1 1 4 W.S. Central 968 579 260 74 30 25 53
New York City, NY 881 617 191 53 15 5 33 Austin, TX 69 43 16 7 2 1 2
Newark, NJ 32 16 9 3 1 3 5 Baton Rouge, LA 58 51 5 2 — — —
Paterson, NJ 8 7 1 — — — — Corpus Christi, TX U U U U U U U
Philadelphia, PA 228 132 64 18 8 6 9 Dallas, TX 182 100 47 16 7 12 11
Pittsburgh, PA§ U U U U U U U El Paso, TX 57 36 15 4 2 — 2
Reading, PA 26 23 2 1 — — 1 Fort Worth, TX U U U U U U U
Rochester, NY 113 92 14 2 4 1 4 Houston, TX 295 161 91 23 9 11 13
Schenectady, NY 22 18 4 — — — 3 Little Rock, AR U U U U U U U
Scranton, PA 26 20 4 2 — — 2 New Orleans, LA U U U U U U U
Syracuse, NY 6 4 2 — — — 1 San Antonio, TX 182 112 50 14 6 — 17
Trenton, NJ 22 15 6 1 — — — Shreveport, LA 39 22 14 2 1 — 2
Utica, NY 12 9 2 — 1 — 1 Tulsa, OK 86 54 22 6 3 1 6
Yonkers, NY 18 12 5 1 — — 1 Mountain 991 642 255 59 15 19 47
E.N. Central 1,387 901 347 81 33 25 76 Albuquerque, NM 103 75 20 7 — 1 6
Akron, OH 40 25 9 2 2 2 1 Boise, ID 59 43 13 2 — 1 3
Canton, OH 39 26 11 1 — 1 5 Colorado Springs, CO 94 62 27 4 1 — 4
Chicago, IL U U U U U U U Denver, CO 82 41 23 10 2 5 4
Cincinnati, OH 63 31 18 3 10 1 5 Las Vegas, NV 220 139 64 11 3 3 10
Cleveland, OH 192 123 44 19 4 2 4 Ogden, UT 32 27 2 3 — — 2
Columbus, OH 224 145 59 17 2 1 17 Phoenix, AZ 145 78 49 8 5 5 7
Dayton, OH 98 65 27 3 1 2 6 Pueblo, CO 20 16 4 — — — 1
Detroit, MI 104 54 35 11 3 1 4 Salt Lake City, UT 116 76 27 9 2 2 3
Evansville, IN 43 29 13 1 — — 6 Tucson, AZ 120 85 26 5 2 2 7
Fort Wayne, IN 52 36 13 1 1 1 1 Pacific 1,243 820 292 80 33 18 117
Gary, IN 10 4 5 — — 1 — Berkeley, CA 12 7 4 1 — — 2
Grand Rapids, MI 40 29 6 2 1 2 4 Fresno, CA U U U U U U U
Indianapolis, IN 150 91 45 7 3 4 6 Glendale, CA 31 27 3 — 1 — 8
Lansing, MI 44 32 8 2 2 — 1 Honolulu, HI 70 54 11 2 3 — 6
Milwaukee, WI 45 32 11 1 — 1 5 Long Beach, CA 63 49 8 4 2 — 10
Peoria, IL 35 20 12 — 1 2 2 Los Angeles, CA 216 130 50 21 9 6 25
Rockford, IL 47 29 11 5 2 — 2 Pasadena, CA 17 11 3 2 — 1 1
South Bend, IN 37 30 4 — — 3 3 Portland, OR 99 66 28 2 2 1 4
Toledo, OH 79 67 8 2 1 1 4 Sacramento, CA 149 95 35 12 4 3 12
Youngstown, OH 45 33 8 4 — — — San Diego, CA 45 25 11 5 4 — 5
W.N. Central 541 330 132 48 9 21 39 San Francisco, CA 93 65 20 7 — 1 12
Des Moines, IA 80 49 22 6 1 2 4 San Jose, CA 163 113 40 8 2 — 18
Duluth, MN 24 19 3 2 — — 3 Santa Cruz, CA 27 18 8 — 1 — 2
Kansas City, KS 15 4 8 3 — — 1 Seattle, WA 114 67 35 6 3 3 8
Kansas City, MO 64 35 23 6 — — 4 Spokane, WA 50 26 18 3 1 2 —
Lincoln, NE 29 24 4 1 — — 5 Tacoma, WA 94 67 18 7 1 1 4
Minneapolis, MN 62 35 17 3 3 4 4 Total¶ 9,099 5,874 2,221 585 226 191 541
Omaha, NE 77 55 13 5 1 3 6
St. Louis, MO 63 27 13 10 2 10 6
St. Paul, MN 67 51 8 7 — 1 3
Wichita, KS 60 31 21 5 2 1 3
U: Unavailable.     —:No reported cases.
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its 
occurrence and by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
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